INDEX TO VOLUME 48—1980

INDEX TO AUTHORS

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

ABE, M., (O) 109, (A) 493, 500
ABREU, A., (A) 476
ACOCELLA, G., (A) 343
AHMED, H. A., (A) 225, 476
AIKAT, B. K., (A) 238
AJZEN, H., (A) 89
AKIMORI, N., (A) 494
AKIYAMA, T., (A) 503
ALLEN, J., (A) 461
ALMEIDA, J. D., (A) 93, 95
ALMEIDA NETO, E., (O) 291
ALONSÓ, J. M., (A) 92
ALUOCH, J. A., (A) 239
AMBIKAPATHY, A., (A) 86
ANAND, L. C., (A) 85
ANÇÃO, M. S., (A) 89
ANDERS, R. F., (A) 349
ANDERSON, R., (A) 469
ANTIA, N. H., (O) 167, 172, 178, 183, 189, (A) 350, 352, 354, 354, 354, 355
ANTIN, U. S., (A) 479
APISARNTHANARAX, P., (A) 229
APONTE-VÁZQUEZ, J., (O) 159
ARAKAWA, I., (A) 467
ARÁNZAZU, N., (E) 62, (A) 93, 351
ARGELLIES, J. L., (A) 98
ARIOLI, V., (A) 343
ARIZA, A., (A) 466
ARMSTRONG, E. L., (A) 86
ASAMOTO, H., (A) 230
ASCH, L., (A) 467
ATHKAMBHIRA, S., (A) 99
ATLAW, T., (A) 225
AUTENSHLYUS, A. I., (A) 106
AWASTHI, K. N., (A) 224
AYESA, C., (A) 466

BADDAR, M. R., (A) 229
BADENOCH-JONES, P., (A) 473
BAEHNER, R., (A) 461
BAILIN, P. L., (A) 241
BALASUBRAHMANYAM, M., (A) 94
BALIÑA, L. M., (A) 93
BALRAJ, V., (O) 397
BANCK, G., (A) 85
BAQUILLON, G., (A) 464
BAROCCI, S., (C) 69
BARROS, C., (O) 291
BARROW, W. W., (O) 382
BARRUCAND, D., (A) 225
BARTON, R. P. E., (A) 226, 226, 345
BASSET, A., (A) 361
BATESON, E. M., (A) 87
BAYLISS, J. H., (A) 342
BEACH, R. B., (A) 237
BECHAR, M., (A) 227
BECHELLI, L. M., (O) 126, (A) 477
BEDI, B. M. S., (A) 94, 458
BEIGUELMAN, B., (A) 223, 357
BEK, E., (A) 363
BELDA, W., (A) 461
BELDA, JR., W., (A) 461
BELEHU, A., (B) 218, (A) 225, (O) 247, (A) 476
BELLAHSENE, A., (A) 222
BENO, M., (A) 105
BEOHAR, P. C. (A) 473
BERGEL, M., (C) 67
BERGH, O. J., (A) 471
BERGQUIST, R., (A) 94
BERGTHOLDT, H. T., (A) 237
BERMAN, P. A., (A) 85
BESON, C. A., (A) 342
BEVANS, L., (O) 285
BEYLOT, C., (A) 357
BEYLOT, J., (A) 357
BHAMARAPRAVATI, N., (A) 99
BHARADWAJ, V. P., (A) 224, 230
BHARGAVA, N. C., (A) 94
BHASKARAM, P., (A) 479
BHATTACHARYA, P. K., (A) 238
BINFORD, C. H., (Ob) 322, (A) 493, 494, 494, 495
BIOULAC, P., (A) 357
BIRDI, T. J., (O) 172, 178
BJORVATN, B., (A) 94, (O) 260
BJUNE, G., (O) 30, (A) 350, 352, 469
BLOCH-MICHEL, E., (A) 230
BLOOM, B. R., (A) 94, 239, 502
BOLIVAR, R., (A) 240
BOOBIS, A. R., (A) 461
BOTHA, P., (A) 85
BOUGHTON, C. R., (A) 82
BOURGEOIS-DROIN, CH., (A) 87
BOURNE, A. J., (A) 465
BOURREL, P., (A) 362
BOXER, L., (A) 461
BRADLEY, D. J., (A) 478
BRAND, M. B., (N) 451
BRAND, P. W., (A) 237

Brennan, P. J., (O) 382
Bretana, A., (A) 493
Brodie, M. J., (A) 461
Broekman, J. M., (A) 231
Brooksby, J. B., (A) 243
Brown, D. J., (A) 461
Brown, H., (A) 102
Brown, H. L., (A) 495
Browne, S. G., (N) 77, (B) 80, (A) 234, (N) 451
Bryceson, A., (B) 339
Buchanan, T. M., (A) 505
Buchmann, H., (B) 219
Bullock, W. E., (A) 82
Burkhardt, K. R., (A) 479
Busch, S., (A) 346
Bussel, A., (A) 87
Byun, H. W., (A) 240

Callanan, J. J., (A) 85
Campinchi, R., (A) 230
Campos, M. P., (A) 102, 102
Cao, S. N., (A) 475
Carayon, A., (A) 85, 92
Cardama, J. E., (A) 93, (N) 444
Carillo Casaux, D., (A) 465
Carillo Montesinos, J. M., (A) 465
Carmel, R., (A) 98
Carosella, E., (A) 93
Carrica, A., (A) 226
Castillo, F. de la C., (A) 93
Chacko, C. J. G., (O) 41, 397, (A) 478
Chan Pin Jin, J., (A) 93, 352
Chandi, S. M., (O) 41
Chang, Z. N., (A) 471
Chaparas, S. D., (O) 388
Chapman, R. F., (A) 221
Chapron, D. J., (A) 222
Chaudhuri, S., (A) 223, 235
Chaves, J., (A) 351
Chehl, S. P. K., (A) 490
Cheng, Y. T., (A) 507
Chiewsilp, P., (A) 99
Chirachariyavej, T., (A) 99
Chiron, J.-P., (A) 87, 226, 227, 465
Christian, M., (O) 397
Cinn, Y. W., (A) 231
Closs, O., (A) 350, 352
Coats-Stephen, M., (A) 243
Cocito, C., (C) 442
Collins, F. M., (O) 402, (A) 497
Colston, M. J., (A) 222, 475, 491
Consigli, C. A., (A) 88
Contreras Dueñas, F., (Ob) 206, 443, 443
Convit, J., (E) 62, (A) 93, 351, 493, 502
Coppi Vaz, C. A., (A) 351
Cottenot, E., (A) 230
Cottenot, F., (A) 87
Coudert, J., (A) 227
Coulanges, M., (B) 339
Coulanges, P., (B) 339
Coursaget, P., (A) 87
Crofton, J., (A) 243

D'Amaro, J., (A) 478
Darnis, F., (A) 464
Das, P. K., (A) 462
Dash, R. J., (A) 88
Dastur, D. K., (O) 140, 149, (A) 470
Daver, S. M., (O) 140, 149
Davey, T. F., (A) 357
Davidovitz, S., (A) 227
Dayal, S. G., (A) 468
de Castro, I. M., (A) 346
Dechavanne, M., (A) 222
Delia, S., (A) 88
Delville, J., (C) 442
de Maar, E. W. J., (A) 458
Denis, F., (A) 87, 226, 227, 465
Deodhar, N. S., (A) 83
DeSantis, A., (A) 470
Desikan, K. V., (O) 48, (A) 91, 91, 96, 223, 343, (O) 408
deVries, R. R. P., (A) 99, 478
Dewarker, P. R., (A) 236
deWit, M., (A) 223
Dharmendra, (B) 339
Dhople, A. M., (O) 402
Dias, M. H. de P., (A) 103
Dickson, Jr., E. T., (A) 462
Diesselhoff-Den Dulk, M., (A) 93
Discamps, G., (A) 344
Dobek, A. S., (A) 462
Dollery, C. T., (A) 461
Dols, M. W., (A) 82
Donadio, Jr., J. V., (A) 104
Donham, K. J., (O) 414
Dorey, C., (A) 230
Doutre, M.-S., (A) 357
Draper, P., (O) 15
Dry, P., (A) 354
Dufier, J. L., (A) 230
Dumont, M., (A) 227
Duncan, M. E., (A) 352, 465, 472
Dutta, U., (A) 238
Dyer, R. F., (A) 102
Dymock, R. B., (A) 465

Ebong, O. O., (A) 344
Edelman, R., (A) 88
Eggelte, T. A., (A) 223
Ekambaram, V., (A) 234
Elisha, G., (A) 85
Elonen, E., (A) 464
El-Shiemy, S., (A) 229
El-Zawahry, K., (A) 234
El-Zawahry, M., (A) 234
Enna, C. D., (A) 102, 227
Entwistle, C., (A) 99
Erickson, S. B., (A) 104
Estrada-Parra, S., (O) 159

Fauxpoint, B., (A) 226
Ferracci, C., (A) 464
Ferraresi, R. W., (A) 504
Ferri, R. G., (A) 351
Festenstein, H., (A) 478
ffytche, T. J., (A) 237
Fields, J. P., (A) 94
Fieldsteel, A. H., (O) 267, (A) 491
Figueiredo, A. A., (A) 358
File, S. K., (A) 356
Fine, P. E. M., (A) 478
Fliess, E. L., (A) 93, 348, 351
Floyd, M., (A) 240
Fonseca, L. de S., (A) 104, 104
Forsgren, A., (A) 85, 222
Fournier, G., (A) 222
Fraser, C. E. O., (A) 363
Fregnan, R. C., (O) 126
Frist, T. F., (O) 303
Fritschi, E. P., (O) 41, 397
Fukunishi, Y., (O) 408, (A) 493, 494, 494, 495
Fukushi, K., (A) 499
Fumarola, D., (A) 470
Funazu, T., (A) 462

Gadoth, N., (A) 227
Gallego Garbajosa, P., (A) 477
Ganapati, R., (A) 236
Garcia González, J., (A) 93
Garrido, M., (A) 466
Garrigue, R., (A) 342
Gatner, E. M. S., (A) 346, 469
Gatti, J. C., (A) 93
Géniaux, M., (A) 478
Gerone, P. J., (A) 495
Gervazoni, B., (A) 464
Getty, P., (A) 102
Ghosh, P. K., (A) 362
Ghosh, S., (A) 223, 235
Giardina, A., (A) 476
Gidoh, M., (A) 462, 496, 499
Gillis, T. P., (A) 505
Giradeau, P., (A) 344
Girdhar, A., (A) 229
Girdhar, B. K., (O) 48, (A) 223, 224, 343
Girling, D. J., (A) 344
Glatthaar, E., (A) 346
Godal, T., (A) 95
Godeau, P., (A) 235
Goihman-Yahr, M., (E) 435
Goiriena de Gandarias, F. J., (A) 466
Gold, C. H., (A) 89
Golitz, L. E., (A) 347
Gontijo Filho, P. P., (A) 104, 104
González Cruz, O., (O) 159
Gordon, G., (N) 76, 214, 215, 215, 217, 334, 338
Goudeau, A., (A) 87
Goyle, S., (A) 96
Grainger, C. R., (A) 358
Griciute, L., (A) 463
Griffiths, D. L., (A) 243
Grosshans, E., (A) 361
Grove, D. I., (A) 459
Guarneri, B., (A) 476
Guillaume, A., (A) 478
Guinto, R. S., (A) 91, (Ob) 327
Gupta, A. K., (A) 480
Gupta, K. K., (A) 102
Gupta, R. C., (A) 102
Gupta, S. K., (A) 346
Gupte, M. D., (A) 352
Gustot, P., (A) 464
Guyer, J. L., (A) 230
Gyi, M. M., (A) 477

Haddad, N., (O) 126
Hampton, G. H., (A) 238
Han, S. H., (A) 471
Hans, G., (A) 346
Harada, K., (A) 506
Harahap, M., (A) 356
Harboe, M., (E) 193, (A) 350, 352
Hargrave, J. C., (A) 87
Harman, D. J., (A) 353
Harris, E. B., (A) 96, (C) 331
Harverson, G., (A) 227
Hastings, R. C., (E) 62, (N) 78, (E) 439, (A) 490, 498
Hausman, R., (A) 90
Hayashi, A., (A) 103
Hazen, P. G., (A) 105
Hazra, S. K., (A) 223, 235
Hentschel, B., (A) 466
Hermo, J., (A) 225
Herrera, M., (A) 93
Herrerias, J. M., (A) 466
Hilling, M., (A) 99
Hillyard, C. J., (A) 461
Hilson, G. R. F., (A) 222, 475
Hirschberg, H., (A) 471
Hitze, K. L., (A) 344, 481
Hitzeroth, H. W., (A) 99
Hogerzeil, L. M., (A) 345
Holley, K. E., (A) 104
Hsu, K. H., (A) 471
Huang, C. L.-H., (E) 309
Huang, H. S., (A) 475
Hue, S. H., (A) 223
Huikeshoven, H., (A) 223, 462
Humphres, R. C., (A) 504
Hurtrel, B., (A) 233

Imam, S. K., (A) 90
Imkamp, F. M. J. H., (A) 346, 469
Irani, P. F., (A) 354, 354
Irgens, L. M., (O) 1, (A) 358
Irulegui, I., (A) 351
Ishihara, S., (A) 466
Ismail, G., (A) 461
Ito, T., (A) 493, 496, 498

Iwamoto, K., (A) 234
Izumi, S., (A) 502
Izumi, T., (A) 230
Iyengar, B., (A) 231, 347

Jacobson, R. R., (A) 229, 498
Jain, A. K., (A) 94
James, Jr., A. E., (A) 466
Jamil, Z., (A) 480
Jariwala, H. J., (O) 422, 426
Jerez, J., (A) 466
Jesudasan, K., (O) 397
Jesudasan, M., (A) 477
Ji, B. H., (A) 463
Jiang, B. L., (A) 475
Jiménez, A. M., (A) 228
Jirillo, E., (A) 470
Job, C. K., (O) 41, 298, 397
Johnson, A. C., (A) 466
Johnson, F. B., (A) 494
Johnson, S., (A) 466
Johnston, J. H., (A) 467
Jopling, W. H., (C) 211, (A) 228
Joshi, L. D., (A) 468
Juji, T., (A) 502
Junqueira, L. C. U., (O) 291

Kado, M., (A) 230
Kanchana, M. V., (O) 388, (A) 476
Kansky, A., (A) 342
Kapoor, P., (A) 83, 235
Kasai, T., (A) 506
Kasili, E. G., (A) 231
Kaur, S., (A) 89, 346
Kavaler, F., (A) 362
Kawaguchi, Y., (A) 96
Kawatsu, K., (A) 96
Kazda, J., (O) 1, (A) 479, 480
Keats, B. J. B., (A) 237
Keeler, R. F., (A) 479
Kelkar, S. S., (O) 422, 426
Kelly, E. D., (B) 219
Kelman, H. R., (A) 362
Kher, V., (A) 89
Kieffer, D., (A) 467
Kilburn, J. O., (A) 86
Kilgour, J. L., (A) 243
Kilpatrick, G. S., (A) 243
Kim, D. J., (A) 240
Kim, W. S., (A) 231
Kirchheimer, W. F., (A) 96, (C) 331, (A) 490
Kitaichi, M., (A) 230
Klatser, P. R., (A) 462
Klayman, D. L., (A) 462, 497
Kliemann, T. J. A. E., (A) 351, 461
Klingmüller, G., (A) 97, (B) 340, (A) 347
Koch, U., (A) 347
Kohsaka, K., (A) 232, (O) 277, (A) 493, 496, 508
Koide, S., (A) 462
Kok, S. H., (A) 346, 469
Koranne, R. V., (A) 231, 232, 347, 468
Korting, G. W., (A) 346
Koseki, M., (A) 500
Koya, G., (A) 467
Krahenbuhl, J., (A) 504
Krakauer, R. S., (A) 241
Kramer, P. A., (A) 222
Kronvall, G., (A) 95, (O) 260
Kumar, B., (A) 88, 89, 346
Kumar, J. H. R., (O) 431
Kundu, S. K., (A) 223, 235
Kuntz, J. L., (A) 467
Kunugi, K. A., (A) 86
Kuppusamy, P., (A) 103
Kurtz, S. B., (A) 104
Kusaka, T., (A) 494
Kushnir, M., (A) 227

Labat, P., (A) 226
Lagrange, P. H., (A) 97, 223
Lai A. Fat, R. F. M., (A) 93, 352
Laing, A. B. G., (C) 70, (A) 86
Lakhani, R., (A) 352, 355
Lakshiminarayana, C. K., (O) 388
Lancaster, R. D., (A) 222
Landheer, J., (A) 223, 462
Languillon, J., (A) 85, 87, 226, 227
Lasheen, R., (A) 229
Latu, J., (A) 468
Lauer, B. A., (A) 347
Leake, E. S., (A) 471
Lecha, M., (A) 105
Lechat, M. F., (O) 51
Lehto, V.-P., (A) 94
Leiker, D. L., (A) 100, 100, 223, 462
Leininger, J. R., (O) 414
Lennard-Jones, J. E., (A) 86
Lenoir, B., (A) 222
Lerner, R. D., (A) 362
Lessof, M. H., (A) 95
Levan, N. E., (O) 120
Levy, L., (O) 267
Lew, J., (A) 459, 463
Lewis, E. J., (A) 241
Lieberman, J., (A) 98
Lilla, J. A., (A) 347
Lindgren, I., (A) 242
Lindner, E., (A) 94
Lindqvist, K., (A) 94
Linois, H., (A) 362
Liu, Q., (A) 475
Lombardi, C., (A) 461, 477
Louvet, M., (A) 344
Lu, H. T., (A) 227
Lwin, K., (A) 477
Lynch, P., (A) 467

MacDonald, A. B., (A) 363
MacIntyre, I., (A) 461
Madanagopalan, N., (A) 468

MAEDA, H., (A) 502
MAGNA, L. A., (A) 223
MAHADEVAN, P. R., (O) 167, 172, 178, 183, 189
MAHAPATRA, S. B., (A) 467
MAHFOUZ, M. O., (A) 363
MALEVILLE, J., (A) 478
MALIK, S. K., (A) 89
MALULI, A. M., (A) 89
MANGIATERRA, M. L., (A) 92
MANI, M. Z., (A) 344
MARCHIONDO, A. A., (A) 356
MARGARIDO, L. C., (A) 102, 362, 461
MARLET, J. M., (A) 359, 461
MARTIN-GIL, D., (A) 466
MARTÍNEZ, E. A. L. W., (A) 461
MARTÍNEZ-DOMÍNGUEZ, V., (A) 477
MASCANI, M., (A) 101
MASCARO, J. M., (A) 105
MASON, L. H., (A) 94, 502
MASUDA, A., (O) 254
MATHAI, R., (O) 298
MATHEW, M., (A) 344
MATSUI, Y., (A) 230
MATSUMOTO, H., (A) 502
MATSUMOTO, Y., (A) 502
MATSUO, Y., (A) 498
MATSUOKA, M., (A) 96
MATTHEWS, C. M. E., (A) 477
MATTILA, M. J., (A) 464
MAUPAS, PH., (A) 87, 226, 465
MCADAM, K. P. W. J., (A) 347
MCDOUGALL, A. C., (C) 210, (A) 226, (C) 329, (A) 345, 353
MCGEE, M. P., (A) 471
MCNEELY, D. F., (A) 101
MEHRA, N. K., (A) 352, 478
MEHRA, V., (A) 94, 502
MEHTA, J. M., (A) 228, (C) 332
MEHTA, L. N., (A) 350, 352, 354, 354, 355
MEISEL, S., (A) 464
MELCHIOR, JR., E., (O) 126
MELSOM, R., (A) 352, 472
MENDES, E., (A) 105
MERCIK, S. A., (A) 222
MEYER, R., (A) 467
MEYERS, W. M., (O) 414, (A) 493, 494, 494, 495
MEYNIEL, D., (A) 464
MICHAEL, J. M., (A) 459
MICHELSON, J. B., (A) 89
MILIAN, L. M., (A) 93
MIN, K. U., (A) 223
MINAGAWA, F., (O) 109, 371, (A) 500
MISRA, S. N., (A) 94
MISSON, C. B., (O) 51
MITTAL, M. M., (A) 473
MIYAZAKI, T., (A) 502
MOCELIN, A. J., (A) 89
MOHAN DAS, M. G., (A) 359
MONGE JODRA, V., (A) 466
MONNO, R., (A) 470
MONTAGNA, G., (A) 86
MONTES, G. S., (O) 291
MONZÓN, H., (A) 351
MOON, K. C., (A) 231
MORALES, M. J., (A) 490
MORETTI, G., (A) 357
MORI, T., (A) 232, (O) 277, (A) 493, 496, 508
MORRISON, N. E., (O) 402, (A) 497
MOULDING, T., (A) 224
MSHANA, R. N., (A) 350
MUKHERJEE, A., (O) 48, 408
MUKHERJEE, R., (O) 183, 189
MUKOYAMA, M., (A) 472
MULCHAND, S., (A) 236
MÜLLER, K., (O) 1, (A) 480
MUNAF, A., (A) 360
MUNDERLOH, W., (A) 99
MUNNO, I., (A) 470
MUTATKAR, R. K., (B) 454
MYERS, M. G., (A) 480
MYRVIK, Q. N., (A) 471

NAAFS, B., (C) 209
NAGATA, Y., (A) 498
NAGPAUL, D. R., (A) 105
NAKAGAWA, K., (A) 234
NAKAMURA, K., (A) 490, 492
NAKAMURA, M., (A) 507
NAKAMURA, R. M., (A) 503
NAKANO, H., (A) 234
NARAYANA, A. S. L., (A) 243
NARAYANAN, R. B., (A) 352
NARITA, M., (A) 462, 499
NASUTION, A. H., (A) 356
NATH, I., (A) 352, 473
NATHANI, D., (A) 102
NAVALKAR, R. G., (O) 388, (A) 476
NAYYAR, M., (A) 468
NEELAN, P. N., (A) 360
NEGASSI, K., (A) 352
NEL, E. E., (A) 479
NELSON, K. E., (A) 501
NEUVONEN, P. J., (A) 464
NEVES, R. G., (O) 126
NI, G. X., (A) 463
NIGAM, P., (A) 224, 468
NIMBALKAR, S. T., (A) 228
NISHIURA, M., (A) 493, 494
NOBREGA, R. C., (A) 101
NOCERA, A., (C) 69
NOMAGUCHI, H., (O) 277, (A) 508
NOORDEEN, S. K., (A) 360
NOUSSITOU, F. M., (A) 228, 477
NUNZI, E., (B) 340
NUTI, M., (A) 88, 89
NWUDE, N., (A) 344
NYEIN, M.-M., (O) 277

OCHSNER, P. E., (A) 90
O'CONNOR, R. J. J., (A) 343

Oehling, A., (A) 466
Ohkawa, S., (A) 502
Okada, S., (O) 408, (A) 493, 494, 506
Olsthoorn, P. G. M., (A) 90
Oommen, P. K., (A) 103
Opromolla, D. V. A., (A) 90, 95
Orgiazzi, J., (A) 222
Ortiz, Y., (O) 159
Osaka, R., (A) 236
Oshima, S., (A) 230
Ozaki, M., (A) 230
Ozawa, T., (O) 109, (A) 500, 500

Pacin, A., (A) 348
Pagnano, P. M. G., (O) 126
Palande, D. D., (A) 363
Palk, S. H., (A) 240
Pamba, H. O., (A) 231
Panchanadam, M., (A) 468
Pandey, N. R., (A) 224
Park, B. K., (A) 461
Park, S. M., (A) 223
Parmar, R. S., (A) 238
Parry, W. D. H., (A) 465
Parvez, M., (A) 94
Pasricha, N., (A) 238
Patel, P. J., (A) 476
Pathania, A. G. S., (A) 238
Patole, A. R., (A) 479
Pattyn, S. R., (O) 7, (A) 83, (C) 211, (A) 464
Pau, H.-W., (A) 347
Pedley, J. C., (A) 353
Pennec, J., (A) 87
Penttinen, K., (A) 95
Perez Perez, B., (A) 466
Pernambuco, J. C. de A., (A) 90
Pershin, G. N., (A) 344
Petit, J., (A) 464
Pettit, J. H. S., (N) 76, 76
Pfaltzgraff, R. E., (B) 339
Phillips, M. A., (A) 236
Pinardi, M. E., (A) 93, 351
Pineda, A. A., (A) 104
Pinto, Jr., W., (A) 223
Piot, P., (C) 211
Podoplelov, I. I., (A) 232, 472
Pondman, K. W., (A) 462
Portaels, F., (O) 7, (C) 330
Porwal, G. L., (A) 470
Poupon, R. Y., (A) 464
Prabhakaran, K., (A) 96, (C) 331
Prasad, L. S. N., (A) 238
Pritchard, J., (A) 478
Pupkoff, R., (A) 464
Pursley, T. V., (A) 229

Quintanilla, E., (A) 466

Rabello, F. E., (E) 318
Radhakrishnan, S., (A) 230
Rajan, M. V., (A) 344
Rajasekar, R., (A) 230
Ramos, O. L., (A) 89
Ramu, G., (A) 91, 91, 96, 229, 230, (O) 408
Randazzo, S. D., (A) 476
Rao, P. S. S. S., (O) 298
Rastogi, G. K., (A) 88
Rathore, B. S., (A) 85
Ravioli, R., (A) 464
Ray, D., (A) 473
Rea, T. H., (A) 98, (O) 120, 285, 473
Reddy, E. R., (A) 466
Rees, R. J. W., (A) 228, 462
Reitan, L., (A) 476
Revankar, C. R., (O) 140, (A) 236
Rey, J. L., (A) 106
Reza, K., (A) 90
Richard, J., (A) 103
Richter, M., (O) 18
Ridley, D. S., (O) 135, (A) 228
Ridley, M. J., (O) 135, (A) 228, 473
Rivaud, C., (A) 226
Roberts, J. L., (A) 241
Rodríguez, F. N., (A) 102
Rojas-Espinosa, O., (O) 159
Ross, W. F., (N) 337
Rossi, E., (A) 86
Rostant, M., (A) 90
Rotberg, A., (A) 353, 460
Roth, A. M., (A) 89
Roux, G., (A) 87, 226, 227
Ruiz de Zarate, S., (A) 476
Ryan, M. A., (A) 479

Sadi, A., (A) 89
Saha, K., (A) 473
Sahaya, S., (A) 238
Saikawa, K., (O) 109, (A) 360, 361
Saint-André, P., (A) 343, 344, 464
Saito, T., (O) 109
Salgame, P. R., (O) 172, 178
Samsoen, M., (A) 361
Samuel, N. M., (A) 228
Sanada, K., (A) 500
Sandbank, U., (A) 227
Sansarricq, H., (O) 51, (Ob) 66, 206, (A) 477
Sansonetti, Ph., (A) 87
Saoji, A. M., (O) 422, 426
Sardi, F., (A) 468
Sarrat, Ph., (A) 478
Sasaki, N., (A) 472
Sato, N., (A) 491
Satterwhite, T. K., (A) 240
Sauder, D. N., (A) 241
Saxena, H. M. K., (A) 468
Saxena, K. C., (A) 480
Saxena, R. P., (A) 480
Scheinberg, M. A., (O) 254
Schlecht, B., (A) 344

SCHMIDT, C., (A) 225
SCOVILL, J. P., (A) 462
SEAL, K. S., (O) 51
SEBAI, Z. A., (A) 477
SEBILLE, A., (A) 349, 362
SEHGAL, S., (A) 238
SEHGAL, V. N., (B) 454, (A) 468
SELEZNEVA, S. P., (A) 232, 472
SELVAPANDIAN, A. J., (A) 103, 477
SENGUPTA, U., (A) 91, 91
SERJEANTSON, S., (A) 237, 354
SEYDEL, J. K., (O) 18
SHAH, J. S., (O) 140
SHANNON, E. J., (A) 490
SHARDA, D. P., (A) 94
SHARMA, A. K., (A) 352
SHELLEY, W. B., (A) 241
SHEPARD, C. C., (C) 68, (O) 371, (A) 492
SHERI, S., (A) 229
SHESKIN, J., (A) 86, 91
SHETTY, V. P., (A) 350, 354, 354, 354
SHIPLEY, D. E., (A) 238
SHIRAMBA, T. L., (A) 231
SIALY, R., (A) 88
SIDDIQUE, M. I. A., (A) 224
SINGH, C. M., (A) 344
SINGH, R., (A) 231, 232, 347
SINGH, S., (A) 238, 473
SINHA, S., (A) 91
SIVARAJAN, S., (A) 230
SKINSNES, O. K., (C) 71, 333, (A) 355
SMITH, D. G., (A) 91, 101
SMITH, J. H., (A) 356
SMITH, T., (A) 501
SMITH, W. C. S., (A) 479
SOBICH, E., (A) 97
SOETERS, A., (A) 223
SOLOMON, S., (A) 468
SORO, S., (A) 88
SPECK, S. M., (A) 501
SREEVATSA, (A) 343
SRINIVAS, H. V., (A) 352, 355
SRINIVASAN, K. R., (A) 230
SRITHARAN, V., (A) 230
SRIWASTAVA, P., (A) 468
SRIWASTAVA, R. N., (A) 224
STABILE, N. E., (A) 89
STEELE, R. W., (A) 480
STENMAN, S., (A) 94
STEVENS, A., (A) 478
STEVENS, K. M., (A) 233
STONER, G. L., (A) 94, 225, (O) 247, (A) 476
SUBRAMANIAM, S., (A) 468
SUDO, L., (A) 358
SUGIYAMA, K., (A) 502
SUNDARESAN, T., (A) 477
SUNDEEN, J., (A) 241
SUPRASERT, S., (A) 501
SUSHIDA, K., (A) 96, 234
SUTHERLAND, I., (A) 84, 242
SVAAN, J., (A) 464
SZARFMAN, A., (A) 92

TAKAYAMA, K., (A) 86
TALIB, S., (A) 90
TAMONDONG, C. T., (A) 477
TANDON, A., (A) 480
TANEMURA, M., (A) 96
TANG, Q. G., (A) 463
TARABINI, G. C., (A) 89
TARABINI, G. C. L., (A) 89
TAYLOR, C. R., (O) 285
TAYLOR, P. M., (O) 397
TEDESCO-MARCHESE, A. J., (O) 291
TEIXERA, A. C., (A) 103
TELLO, E. E., (A) 349
TEN DAM, H. G., (A) 481
TERASAKI, P. I., (A) 473
TERENCIO DE LAS AGUAS, J., (A) 86, 361, 464
TEXIER, L., (A) 478
THALAYAN, K., (A) 228
THAMER, G., (A) 89
THIAGARAJAN, V., (A) 230
THOMPSON, D. E., (A) 237
THYAGARAJAN, S. P., (A) 468
TIMOFEEVA, L. N., (A) 106
TOKUNAGA, T., (A) 503
TOLENTINO, M. M., (A) 90
TOMATIS, L., (A) 463
TORRAS, H., (A) 105
TOUW, J., (A) 225, (O) 247, (A) 476
TRAMONT, E. C., (A) 462
TRIPATHY, S. P., (A) 243
TROFIMOV, G. K., (A) 106
TSAI, L. C., (A) 471
TSUKAMURA, M., (A) 363
TSUTSUMI, S., (A) 462, 496, 499
TURK, J. L., (A) 473
TURNER, T. W., (A) 465

ULRICH, M., (E) 62, (A) 93, 351
URCUYO, F. G., (A) 228

VAIDYA, M. C., (A) 478
VALLA, M. C., (A) 227
VAN DEN BROEK, H., (A) 363
VAN DER MEULEN, J., (C) 208
VAN DYCK, E., (C) 211
VAN EDEN, W., (A) 478
VAN FURTH, R., (A) 93, 352
VAN LANDINGHAM, R., (O) 371
VAN ROOD, J. J., (A) 99, 478
VAUTRAVERS, PH., (A) 467
VEDY, J., (A) 226
VELIATH, A. J., (A) 94
VENKATARAMAN, P., (A) 243
VENKATESAN, K., (A) 224, 230
VERGHESE, A., (O) 431
VIDYASAGAR, P. B., (A) 354
VILLON, A., (A) 106

VINCENT, M. M., (A) 480
VINET, J., (A) 101
VIRMANI, V., (A) 96

WAGER, O., (A) 95
WALKER, L. L., (O) 371
WALL, J. R., (A) 95
WALSH, G. P., (A) 98, 493, 494, 494, 495
WALTER, H., (A) 99
WALTER, J., (O) 51, (Ob) 206, (A) 477
WALTERS, B. A., (A) 95
WAMOLA, I. A., (A) 231
WANG, H. Y., (A) 475
WANG, S. Y., (A) 463
WARING, III, G. O., (A) 89
WARNDORFF, T., (C) 441
WARREN, A. G., (A) 227
WATERS, M. F. R., (A) 86
WATSON, B., (A) 478
WATSON, S. R., (O) 402
WAUDBY, H., (A) 353
WECHSLER, B., (A) 235
WEDDELL, A. G. M., (C) 329
WEINER, M. H., (A) 243
WEISSELBERG, C., (A) 235
WEMPE, E., (O) 18
WERTHEIN, L. J., (A) 476
WHEELER, P. R., (O) 15
WHITE, G. DE L., (A) 225
WHITTINGHAM, S., (A) 473
WILLIAMS, R., (A) 243
WILSON, C. B., (A) 104
WILSON, S. R., (A) 237
WIRAWAN, R., (A) 468
WIRJADI, B., (A) 468
WOLF, E., (A) 478
WOLF, R. H., (A) 495
WU, Q. X., (A) 475

YAAR, I., (A) 91
YAMAURA, N., (A) 503
YELLAPURKAR, M. V., (A) 83, 235
YOGI, Y., (A) 490, 492
YOKOMURO, K., (A) 499
YONEDA, K., (O) 277, (A) 493, 496, 508
YOSHINO, Y., (O) 109, (A) 500

ZIERSKI, M., (A) 363

INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

Acedapsone,
chemoprophylaxis against leprosy with. Noordeen, S. K., *et al.* ....(A) 360

Acid,
ascorbic, effect on blood levels of DDS. Venkatesan, K., *et al.* ....(A) 224

Acid-fast characteristics,
non-cultivable bacilli, isolation of, in sphagnum and moss vegetation, by foot-pad technique in mice. KAZDA, J., *et al.* ....(O) 1

Africa,
Central, unclassified mycobacterial strains susceptible to dapsone, isolated from the environment in. PORTAELS, F. ....(C) 330
plants used in the treatment of leprosy in. Nwude, N. and Ebong, O. O. ....(A) 344
West, barefoot doctors fighting leprosy in. ....(N) 451
—, first case of leprosy with secondary resistance to dapsone in. Pattyn, S. R., *et al.* ....(A) 464

American Leprosy Missions (ALM),
administrative position announced. Brand, M. B. ....(N) 451

Amyloidosis(es),
amyloid fibril proteins, found in Papua New Guinean and other. Anders, R. F. ....(A) 349
renal, in Blacks. Gold, C. H. ....(A) 89
secondary, in the tropics, leprosy, filariasis and malaria as causes of. McAdam, K. P. W. J. ....(A) 347

Antia, Dr. N. H.,
personal. ....(N) 78

Antibiotics,
aminoglycoside . . . measurement, some aspects of. Botha, P., *et al.* ....(A) 85
and suppression of lymphocyte functions in. Banck, G. and Forsgren, A. ....(A) 85

Antibody(ies),
anti-mycobacterial, *in vitro* synthesis of, in skin lesion biopsies. Lai A. Fat, R. F. M. ....(A) 352
circulating, to connective tissue microfibrils and dermal immunoglobulin deposits, in leprosy. Lindner, E. ....(A) 94
demonstration of, against *M. leprae*, in IgG and IgM, in pregnant and non-pregnant lepromatous leprosy sera. Melsom, R. and Duncan, M. E. ....(A) 472
immunofluorescence test for detection of, in *M. tuberculosis*. Mahfouz, M. O., *et al.* (A) 363
in leprosy sera, assay for, reacting with RNP, using crossed immunoelectrophoresis with intermediate gel. STONER, G. L., *et al.* ....(O) 247
leprous, intraocular production of. Campinchi, R., *et al.* ....(A) 230
production, effect of clinically equivalent dapsone and rifampin doses on, and delayed-type hypersensitivity to sheep red blood cells, in mice. Nagata, Y. and Ito, T. ....(A) 498
specific . . . response, impairment of Jones-Mote hypersensitivity and, against depolymerized flagellin, in lepromatous leprosy. Saha, K., *et al.* ....(A) 473

Antigen (hepatitis),
and infectious diseases. deVries, R. R. P. and van Rood, J. J. ....(A) 99
— leprosy. NOCERA, A., *et al.* ....(C) 69
—, in Thailand. Chiewsilp, P., *et al.* ....(A) 99
and parasitic diseases, correlation. Delia, S., *et al.* ....(A) 88
— serum protein allotypes, immunogenetic background analysis, of Japanese leprosy patients by. Sugiyama, K., *et al.* ....(A) 502

Australia, in Egypt, in lepromatous leprosy. Sheri, S., *et al.* .....(A) 229
detection of Hb_sAg, in leprosy patients. Goiriena de Gandarias, F. J., *et al.* .....(A) 466
"e" antigen, in leprosy. Nuti, M., *et al.* .....(A) 89
HLA—A, B and C, in South Indian leprosy families. Wolf, E., *et al.* .....(A) 478
HLA—DR, in tuberculoid and lepromatous leprosy. Rea, T. H. and Terasaki, P. I. ...(A) 473
HLA segregation of tuberculoid leprosy, confirmation of DR2 marker. van Eden, W., *et al.* .....(A) 478
serum titers of surface, in hepatitis B virus infection, in leprosy. Chiron, J.-P., *et al.* .....(A) 226
subtypes of HB_sAg, distribution and occurence, in blood donors and patients with liver diseases and leprosy, in Tamil Nadu, India. Thyagarajan, S. P., *et al.* .....(A) 468

Antigen (leprosy),
analysis of *M. leprae*. Closs, O., *et al.* .....(A) 350
and phytohaemagglutinin, simultaneous stimulation with, *in vitro* lymphocyte stimulation, in leprosy. Bjune, G. .....(A) 350
characterization of *M. leprae* "specific." Gillis, T. P. and Buchanan, T. M. .....(A) 505
Dharmendra, comparative study with Mitsuda. Sinha, S., *et al.* .....(A) 91
—, standardization of. Sengupta, U., *et al.* .....(A) 91
evaluation of *M. vaccae* to *M. leprae*. NAVALKAR, R. G., *et al.* .....(O) 388
liver tissue, water soluble, cross-reactions between serum. Negassi, K., *et al.* .....(A) 352
lymphocyte responses to, variation of *in vitro*, in borderline tuberculoid leprosy. BJUNE, G. .....(O) 30
mycobacterial ribosomal (ribonucleoprotein [RNP]) assay for antibodies in leprosy sera reacting with, using crossed immunoelectrophoresis with intermediate gel. STONER, G. L., *et al.* .....(O) 247
species-specific lipid. BRENNAN, P. J. and BARROW, W. W. .....(O) 382

Antigen (miscellaneous),
in *Nocardia caviae*, detection, cross-reacting with antigen No. 21, using a lepromatous leprosy serum pool as antibody reagent. BJORVATN, B. and KRONVALL, G. .....(O) 260
insoluble, organization of allergic granulomas and dependence on. McGee, M. P., *et al.* .....(A) 471

Argentina,
IV Reunión Leprológica (Hansenológica) del Cono Sud and V Reunión Anual de Dermatólogos Latinoamericanos del Cono Sud take place in Buenos Aires. .....(N) 212
further details on IV Reunión Leprológica (Hansenológica). Cardama, J. E. .....(N) 444

Armadillo (nine-banded) (*Dasypus novemcinctus*),
lepromin, leukocyte inhibiting factor (LIF) production, from human lymphocytes of healthy donors stimulated by. Fumarola, D., *et al.* .....(A) 470
macrophages, *M. leprae* inoculated, ultrastructural features of multiplication of leprosy bacilli in. Fukunishi, Y., *et al.* .....(A) 494
mycolic acids analysis, in mycobacteria from lesions of, with naturally acquired leprosy-like disease and experimental . . . leprosy. Kusaka, T., *et al.* .....(A) 494
naturally acquired leprosy-like disease, joint study on. Nishiura, M., *et al.* .....(A) 493
—, of wild . . . , ultrastructure of lepromatous lesions. Marchiondo, A. A., *et al.* .....(A) 356
report on . . . studies in Paraguay. Gordon, G. .....(N) 215
serum angiotensin-converting enzyme, transcobalamin and lysozyme in normal and lepromatous. Rea, T. H., *et al.* .....(A) 98
water soluble liver tissue antigens of, and man, cross-reactions between serum proteins and. Negassi, K., *et al.* .....(A) 352

Armauer Hansen Research Institute (AHRI),
AHRI Research Digest: First Ten Years of Leprosy Research, 1970–1980, review of. Belehu, A., ed. .....(B) 218
immunology conference held at. .....(N) 447
publication of *AHRI Research Digest* announced. .....(N) 212
ten years activity at, immunological aspects of leprosy, prospects for further work. HARBOE, M. .....(E) 193

Art,
and leprosy, in South China. SKINSNES, O. K. ..... (C) 71

Arthritis,
in Hansen's disease. Pernambuco, J. C. de A., *et al.* ..... (A) 90
poly-, in leprosy. Kuntz, J. L., *et al.* ..... (A) 467

Australia,
nerve calcification caused by leprosy in Northern Territory Aboriginals. Bateson, E. M. and Hargrave, J. C. ..... (A) 87

Austria,
Third European Conference of Rehabilitation International planned in. ..... (N) 446

Autoantibodies,
prevalence of, in Korean leprosy patients. Moon, K. C., *et al.* ..... (A) 231

Autoimmunity,
a common denominator in immune complex diseases? Lewis, E. J. and Roberts, J. L. ..... (A) 241

Azulay, Dr. R. D.,
personal. ..... (N) 212

B663,
trial by high performance liquid chromotography for simultaneous analysis of DDS, RFP and, and main metabolites. Tsutsumi, S. and Gidoh, M. ..... (A) 496

Bacterial Index (BI),
average, a reflection of patients' true condition? WARNDORFF, T. ..... (C) 441

BCG,
effect of bases of nucleic acid, on growth of, and *M. bovis* and *M. lepraemurium*. Cheng, Y. T. ..... (A) 507
mixture of *M. leprae* and, immunological changes in indeterminate and lepromatous leprosy patients, and Mitsuda-negative contacts, after inoculation of. Convit, J., *et al.* ..... (A) 93
oral vaccine, tuberculin test, and infection in children under five years of age. Dias, M. H. de P. and Hayashi, A. ..... (A) 103
protection for newborn and young infants? ten Dam, H. G. and Hitze, K. L. ..... (A) 481
trial in South India for tuberculosis prevention. ..... (A) 242
twelve years of vaccination with, and infant leprosy, in Cuba. Abreu, A., *et al.* ..... (A) 476
vaccination, influence on murine leprosy, in C57BL/6 and C3H mice. Lagrange, P. H. and Hurtrel, B. ..... (A) 233
—, protective effect, as indicated by autopsy studies. Sutherland, I. and Lindgren, I. ..... (A) 242

Bedsores,
modified water-air mattress in management of. Gupta, R. C., *et al.* ..... (A) 102

Belgium,
honors Dr. S. G. Browne. Gordon, G. ..... (N) 334

Bible,
Leprosy in the Bible. 3rd ed. Browne, S. G. ..... (B) 80

Biopsy,
from skin lesions, *in vitro* synthesis of anti-mycobacterial antibodies in, in leprosy patients. Lai A. Fat, R. F. M., *et al.* ..... (A) 352
in vitro studies on, from leprosy cases. Goyle, S. and Virmani, V. ..... (A) 96
scrotal, in subsided lepromatous leprosy. Ramu, G. and Desikan, K. V. ..... (A) 96
skin, lactate dehydrogenase zymograms of, in leprosy. SAOJI, A. M., *et al.* ..... (O) 426

Blood,
peripheral, monocyte function, in leprosy patients. MASUDA, A. and SCHEINBERG, M. A. ..... (O) 254

Blood groups,
ABO, and leprosy, in Ethiopia. Ahmed, H. A., *et al.* .....(A) 476

Bolivia,
Ministry of Health issues HD publication. .....(N) 334

Bone,
involvement, dimorphous reaction with, of upper extremities in patient with bacterial endocarditis. .....(A) 348

Brazil,
atypical mycobacteria isolated from sources in Rio de Janeiro, bacteriological study and drug susceptibility test. Fonseca, L. de S. and Gontijo Filho, P. P. .....(A) 104
—, preliminary identification of colony morphologies. Fonseca, L. de S. and Gontijo Filho, P. P. .....(A) 104
Brazilian Phase III of hanseniasis prevention. Rotberg, A. .....(A) 460
details of . . . meetings announced. .....(N) 212
Dr. R. D. Azulay receives appointment. .....(N) 212
endemic HD in São Paulo county, 1976–1977. Lombardi, C. .....(A) 477
epidemiological aspects of hanseniasis, in Paraíba Valley-São Paulo. Nobrega, R. C. and Mascani, M. .....(A) 101

Brobenzoxaldine,
and broxyquinoline, therapeutic trial of a combination, in leprosy treatment. Hazra, S. K., *et al.* .....(A) 223

Browne, Dr. S. G.,
personal. Gordon, G. .....(N) 76
—. Gordon, G. .....(N) 334
—. .....(N) 337

Broxyquinoline,
and brobenzoxaldine, therapeutic trial of a combination, in leprosy treatment. Hazra, S. R., *et al.* .....(A) 223

Burma,
Upper, Singu area, epidemiological information on leprosy in. Martínez Domínguez, V., *et al.* .....(A) 477

Cancer,
lung, pulmonary tuberculosis and leprosy, PHA skin test in patients with, clinical significance. Kado, M., *et al.* .....(A) 230

Candidiasis,
pulmonary. Thiagarajan, V., *et al.* .....(A) 230
systemic, immunodiagnosis of, mannan antigenemia detected by radioimmunoassay, in experimental and human infections. Weiner, M. H. and Coats-Stephen, M. .....(A) 243

Carbamazepine,
in neurological manifestations of leprosy. Jiménez, A. M. and Urcuyo, F. G. .....(A) 228

Cauda equina syndrome,
and ulceromutilant acropathy. Barrucand, D., *et al.* .....(A) 225

Cell(s),
mononuclear-phagocyte series (MPS), ultrastructure of, across leprosy spectrum. Ridley, M. J., *et al.* .....(A) 473

Cell culture,
attempts at *M. leprae* cultivation in. Matsuo, Y. .....(A) 498

Central African Empire,
leprosy in the. Vinet, J. .....(A) 101

Chagas' disease,
potential for immunoprophylaxis. .....(A) 240

Chemoprophylaxis,
against leprosy, with acedapsone. Noordeen, S. K., *et al.* .....(A) 360

Chemotherapy,
association of . . . and immunostimulation, present evaluation, in leprosy. Saint-André, P., *et al.* ....(A) 344
disabilities, incidence of, after commencement of, in leprosy. Keeler, R. F. and Ryan, M. A. ....(A) 479
intermittent, of experimental leprosy, in mice. Colston, M. J., *et al.* ....(A) 222
of infectious diseases, in the Soviet Union. Pershin, G. N. ....(A) 344
— leprosy, discussed. ....(N) 335
— neuritis, in leprosy. Carayon, A. ....(A) 85
of pulmonary tuberculosis, clinical trial of six-month and four-month regimens. ....(A) 241
—, four short-course regimens, controlled clinical trial, for two durations. ....(A) 481
—, side-effects of drug regimens in short-course. Zierski, M. and Bek, E. ....(A) 363
trials reviewed, present situation in Korea. Lew, J. ....(A) 463

Child(ren),
babies, of mothers with leprosy, have small placentae, low birth weights, slow growth. Duncan, M. E. ....(A) 465
clinically healthy, cellular immunity in, of parents with leprosy, in Northern Thailand. Nelson, K. E., *et al.* ....(A) 501
leprosy in. El-Zawahry, M., *et al.* ....(A) 234
—, in a Vietnamese adoptee. Lauer B. A., *et al.* ....(A) 347
—, in preschool age. Revankar, C. R., *et al.* ....(A) 236
tuberculin test, oral BCG vaccine, tuberculosis, in children under five years old. Dias, M. H. de P. ....(A) 103
twelve years of BCG vaccination, infant leprosy, in Cuba. Abreu, A., *et al.* ....(A) 476

Chimpanzee,
leprosy in a, postmortem lesions. LEININGER, J. R., *et al.* ....(O) 414

China,
leprosy and art in South. SKINSNES, O. K. ....(C) 71
leprosy in. Garrigue, R. ....(A) 342
— archeologically recovered bamboo book in. SKINSNES, O. K. ....(C) 333

Classification, of leprosy,
application of clinical and histopathological. Sehgal, V. N., *et al.* ....(A) 468
location of the indeterminate form. Consigli, C. A. ....(A) 88
polar concept, in leprosy, today. RABELLO, F. E. ....(E) 318

Clofazimine,
and thalidomide combined, treatment of steroid dependent cases of recurrent leprosy reaction. Ramu, G. and Girdhar, A. ....(A) 229

Colchicine,
management of necrotizing vasculitis with. Hazen, P. G. and Beno, M. ....(A) 105

Colitis,
pseudomembranous, and rifampin. Acocella, G. and Arioli, V. ....(A) 343
—, probably due to rifampin. Fournier, G., *et al.* ....(A) 222
ulcerative, treatment with thalidomide. Waters, M. F. R., *et al.* ....(A) 86

Collagen,
of permanently damaged nerves, in human leprosy. JUNQUEIRA, L. C. U., *et al.* ....(O) 291

Concanavalin A,
induced suppressor activity, in human leprosy. Nath, I., *et al.* ....(A) 352

Congresses,
Tenth International Congress on Tropical Medicine and Malaria, Manila, Philippines. (N) 335
Third International Leprosy Congress for Arab Countries, Cairo, Egypt. ....(N) 334

Contacts, leprosy,
nerve damage, in leprosy, index branch of radial cutaneous nerve in. Shetty, V. P., *et al.* ....(A) 354

Control, of leprosy,
disability, as a relevant measurement of progress in. Smith, W. C. S., *et al.* ....(A) 479

frequency of hanseniasis, in a university hospital. Figueiredo, A. A. and Sudo, L. L. (A) 358
information system for (OMSLEP). LECHAT, M. F., *et al.* (O) 51
integration with general health services, in Maharashtra. Kapoor, P., *et al.* (A) 83
Leprosy Control Services as an Integral Part of Primary Health Care Programs in Developing Countries. Buchmann, H. (B) 219
organizing a program of. Browne, S. G. (A) 234
prevention and. Mohan Das, M. G. (A) 359
socio-economic conditions and leprosy, private office practice and public outpatient clinic compared, over 30-year period. Tello, E. E. (A) 349
transmission, new dimensions in understanding, impact on priorities. Davey, T. F. (A) 349

Corynebacterium,
strain 0122, a contaminating skin. PIOT, P., *et al.* (C) 211

Costa Rica,
changes announced in HD care. (N) 334

Council for International Organizations of Medical Sciences,
details concerning. Browne, S. G. (N) 450

Cuba,
twelve years of BCG vaccination and infant leprosy in. Abreu, A., *et al.* (A) 476

Cultivation, mycobacteria,
requirements for, of *Treponema pallidum, M. leprae,* and others. Stevens, K. M. (A) 233
The in vitro *Cultivation of the Pathogens of Tropical Diseases*. (B) 455

Dapsone (DDS),
and anti-dapsone antibody, in circulating immune complexes, in leprosy patients. Das, P. K., *et al.* (A) 462
ascorbic acid, effect on blood levels of. Venkatesan, K., *et al.* (A) 224
carcinogenicity of, in mice and rats. Griciute, L. and Tomatis, L. (A) 463
clinically equivalent doses of rifampin and, effect on antibody production and delayed-type-hypersensitivity, to sheep red blood cells, in mice. Nagata, Y. and Ito, T. (A) 498
combined rifampin and, chemotherapy of *M. leprae* infection, in neonatally thymectomized Lewis rat. FIELDSTEEL, A. H. and LEVY, L. (O) 267
high performance liquid chromotography, for simultaneous analysis of RFP, B663 and. Tsutsumi, S. and Gidoh, M. (A) 496
mechanism of action of. HASTINGS, R. C. (E) 65
— folate blocker, studied in *E. coli* cell-free enzyme extracts, compared to sulfonamides (SA). SEYDEL, J. K., *et al.* (O) 18
100 mg daily, preventing permanent nerve damage, in reversal reaction. VAN DER MEULEN, J. (C) 208
oral activated charcoal and . . . elimination. Neuvonen, P. J., *et al.* (A) 464
oxidative effects of . . . derivative, on normal and chronic granulomatous disease polymorphonuclear function. Baehner, R., *et al.* (A) 461
reply to Dr. Van der Meulen's letter. NAAFS, B. (C) 209
secondary . . . resistance, first case of leprosy, in West Africa. Pattyn, S. R., *et al.* (A) 464
—, prevalence, in Gudiyattam Taluk (India). BALRAJ, V., *et al.* (O) 397
unclassified mycobacterial strains susceptible to, isolated from environment, in Central Africa. PORTAELS, F. (C) 330
variable bacilloscopic and morphologic indexes, in leprosy patients treated with rifampin and. Belda, W., *et al.* (A) 461

Dinitrochlorobenzene,
responsivity in untreated leprosy, variations in, beneficial role for anergy. REA, T. H. and LEVAN, N. E. (O) 120

Disabilities,
in leprosy, measurement of progress in leprosy control. Smith, W. C. S., *et al.* (A) 479
incidence, after commencement of chemotherapy, in leprosy. Keeler, R. F. and Ryan, M. A. (A) 479

Drug effects,
antiinflammatory effects of several antileprosy drugs. Gidoh, M., *et al.* .....(A) 462
kinetic discrimination of three sulfamethazine acetylation phenotypes. Chapron, D. J., *et al.* .....(A) 222
statistical tests, results obtained by kinetic method, by proportional bactericidal method. Shepard, C. C. .....(A) 492

Egypt,
Australia antigen, in lepromatous leprosy in. Sheri, S., *et al.* .....(A) 229
Third International Leprosy Congress for Arab Countries meets in. .....(N) 334

Electron microscopy,
improved embedding method, of lepromata. OKADA, S., *et al.* .....(O) 408
study of tuberculoid lesions, proposal of subpolar tuberculoid leprosy. Okada, S. .....(A) 506

Employment (of patients),
causes of unemployment among agricultural laborers with leprosy. Kuppusamy, P., *et al.* .....(A) 103
employer acceptance of the HD patient and other handicapped persons. FRIST, T. F. .....(O) 303
medical certification of leprosy patients, reservation in service for physically handicapped. MEHTA, J. M. .....(C) 332

Endocarditis,
bacterial, dimorphous reaction with bone involvement of upper extremities of patient with. .....(A) 348

Enzyme(s),
studied in hanseniasis patients, activity of glutamic pyruvate transaminase, glutamic oxaloacetic transaminase. Pacin, A. and Fliess, E. L. .....(A) 348

Epidemiology,
case of leprosy, at Charity Hospital, New Orleans. McNeeley, D. F. .....(A) 101
—, autochthonous. Godeau, P., *et al.* .....(A) 235
early detection of infectious leprosy, role of medical personnel. Kapoor, P. and Yellapurkar, M. V. .....(A) 235
endemic HD, in São Paulo County, Brazil. Lombardi, E. .....(A) 477
in Bordeaux (France), 1947–1979, 82 cases managed at dermatological clinic. Texier, L., *et al.* .....(A) 478
— continental France, of leprosy. Samsoen, M., *et al.* .....(A) 361
— Norway, based on national patient registry. Irgens, L. M. .....(A) 358
— Saudi Arabia, leprosy and leprosy care. Sebai, Z. .....(A) 477
— Singu, Upper Burma, of leprosy. Martínez Domínguez, V., *et al.* .....(A) 477
incidence of leprosy, in Martinique, case-finding methods. Argellies, J. L. .....(A) 98
leprosy among factory workers. Ghosh, P. K. .....(A) 362
— survey, in Irabu island. Saikawa, K. .....(A) 361
—, in Yonaguni island. Saikawa, K. .....(A) 360
of leprosy, in the Netherlands, I., 1945–1975. Leiker, D. L. .....(A) 100
—, —, II. Leiker, D. L. .....(A) 100
—, in the Paraíba Valley, São Paulo. Nobrega, R. C. and Mascani, M. .....(A) 101
— psychiatric disturbances, among leprosy patients. KUMAR, J. H. R., *et al.* .....(O) 431
socio-medical characteristics of HD patients. Kelman, H. R. and Kavaler, F. .....(A) 362

Erythema multiforme,
bacterial endotoxin (lipopolysaccharide) as a cause of. Shelley, W. B. .....(A) 241

Erythema nodosum leprosum (ENL),
coagulation abnormalities in patients with. Wirawan, R., *et al.* .....(A) 468

Eschericia coli,
cell free enzyme extracts, mechanism of action of DDS in, compared to sulfonamides. SEYDEL, J. K., *et al.* .....(O) 18

Ethambutol,
inhibition by, of mycolic acid transfer, into *M. smegmatis* cell wall. Takayama, K., *et al.* ....(A) 86

Ethiopia,
AHRI Research Digest: First Ten Years of Leprosy Research. Belehu, A., *et al.* ....(B) 218
—. ....(N) 212
immunology conference held at AHRI. ....(N) 447
leprosy and ABO blood groups in. Ahmed, H. A., *et al.* ....(A) 476
ten years of immunological leprosy studies at AHRI. HARBOE, M. ....(E) 193

Europe,
leprosy returns to. Terencio de las Aguas, J. ....(A) 360

Experimental leprosy,
chemotherapeutic studies against, in mouse foot pad. Ji, B. H., *et al.* ....(A) 463
inoculation with *M. leprae* in asplenic mouse. Nakamura, K. and Yogi, Y. ....(A) 492
intermittent chemotherapy against, in mice. Colston, M. J., *et al.* ....(A) 222

Eye(s),
cataract surgery in leprosy patients. ffytche, T. J. ....(A) 237
intraocular production of leprous antibodies. Campinchi, R., *et al.* ....(A) 230
ocular lesions in leprosy. Carrica, A., *et al.* ....(A) 226

Face,
correction of profile in persons with leprosy. Teixera, A. C. ....(A) 103

Filariasis,
and leprosy and malaria, as causes of secondary amyloidosis, in the tropics. McAdam, K. P. W. J. ....(A) 347

Fluorescent leprosy antibody absorption (FLA-ABS) test,
for detecting subclinical *M. leprae* infection. ABE, M., *et al.* ....(O) 109
sensitivity and specificity of, immuno-epidemiological *M. leprae* subclinical infection studies, in Miyako Islands. Abe, M., *et al.* ....(A) 500

Foot,
clinical evaluation and care of the insensitive. Shipley, D. E. ....(A) 238
management of the insensitive. Brand, P. W. ....(A) 237
tarsal bone disintegration in leprosy. Harverson, G. and Warren, A. G. ....(A) 227
temperature assessment of the insensitive. Bergtholdt, H. T. ....(A) 237

Foot pad (mouse),
chemotherapeutic experimental leprosy infection studies in. Ji, B. H. ....(A) 463
enlargement, measure of induced immunity to *M. leprae*. SHEPARD, C. C., *et al.* ....(O) 371
isolation of noncultivable acid-fast bacilli in sphagnum and moss vegetation by. KAZDA, J., *et al.* ....(O) 1
reply to Dr. Bergel's letter. SHEPARD, C. C. ....(C) 68
twenty years after Shepard's method of inoculation of *M. leprae* in mice. BERGEL, M. ....(C) 67

France,
continental, epidemiologic knowledge of leprosy in. Samsoen, M., *et al.* ....(A) 361
epidemiologic study of 82 cases of leprosy, at Bordeaux dermatological clinic, 1947–1979. Texier, L., *et al.* ....(A) 478
leprosy in, experience in. Bordeaux. Beylot, C., *et al.* ....(A) 357
Société Française de Dermatologie meets. ....(N) 447

Genetics,
markers and leprosy, in South African Negroes, erythrocyte enzyme polymorphisms. Hitzeroth, H. W., *et al.* ....(A) 99
of hanseniasis. Beiguelman, B. ....(A) 357
— leprosy. Serjeantson, S., *et al.* ....(A) 237
susceptibility to lepromatous leprosy, hypothesis. Smith, D. G. ....(A) 101

Germany,
Rehabilitation International announces available publications. ....(N) 212
tuberculosis/leprosy eradication project in Paraguay (GLRA and WHO sponsored) ...(N) 74
update on Malta project (GLRA and WHO sponsored). ....(N) 74

Gilbert, Dr. Maurice,
obituary. Contreras Dueñas, F. ....(Ob) 443

Goodpasture's syndrome,
combined plasmaphoresis and immunosuppression in treatment of. Erickson, S. B., *et al.* ....(A) 104

Granuloma(s),
organization of allergic, dependence on insoluble antigen. McGee, M. P., *et al.* ....(A) 471

Hairless mouse (see nude mouse)

Hand(s),
fingers, in non-lepromatous leprosy. McDougall, A. C. ....(C) 210
—, sites of leprosy bacilli, in pre-relapse patients. Jopling, W. H., *et al.* ....(A) 228
incidence of deformities in, in leprosy. Campos, M. P., *et al.* ....(A) 102
isolated pathological fracture of the capitate bone. Enna, C. D. ....(A) 227
leprosy and thumb reconstruction by opponensplasty or phalangizing the first metacarpal. Brown, H. and Getty, P. ....(A) 102

Haptoglobin(s),
phenotypes, in leprosy. Saoji, A. M., *et al.* ....(O) 422

Health education,
and leprosy. Matthews, C. M. E., *et al.* ....(A) 477
—. Phillips, M. A. ....(A) 236

Hedgehog (*Erinaceus europaeus*),
transmission of human leprosy bacilli to. Klingmüller, G. and Sobich, E. ....(A) 97

Hematocrit,
and sulfonemia, in leprosy patients. Magna, L. A., *et al.* ....(A) 223

Hepatitis,
cholestatic, during treatment with INH and rifampin, toxicity of rifampin. Poupon, R. Y., *et al.* ....(A) 464

Hepatitis B,
lymphocytotoxins in leprosy and asymptomatic. Serjeantson, S. and Dry, P. ....(A) 354
markers, in leprosy. Chiron, J.-P., *et al.* ....(A) 87
markers (HB_eAg, anti-HB_e, anti-HB_c), in the blood. Chiron, J.-P., *et al.* ....(A) 465
relation between envelope markers of . . . and transaminasemia. Chiron, J.-P., *et al.* ....(A) 227

Histoid leprosy,
ultrastructural observation. Ridley, M. J. and Ridley, D. S. ....(O) 135

Histology,
and histochemistry, in striated muscle, in four categories of leprosy. Daver, S. M., *et al.* ....(O) 140

History,
Domus leprosae, community care in medieval England. Bayliss, J. H. ....(A) 342
leprosy in Hawaii, scare advertising at the turn of the century. Chapman, R. F. ....(A) 221
— in medieval Arabic medicine. Dols, M. W. ....(A) 82
— since Hansen. Boughton, C. R. ....(A) 82
Public Health Service Leprosy Investigation Station on Molokai, Hawaii, 1909–1913. Michael, J. M. ....(A) 459

Hypersensitivity,
Jones-Mote, impairment of, specific antibody response against depolymerized flagellin, in lepromatous leprosy. Saha, K., *et al.* ....(A) 473

Hypersensitivity, delayed-type (DTH),
effect of clinically equivalent doses of dapsone and rifampin on antibody production and, to sheep red blood cells, in mice. Nagata, Y. and Ito, T. .....(A) 498

ILEP,
XXIII General Assembly of . . . meets in London. .....(N) 337

Immune complex(es),
circulating, dapsone and anti-dapsone antibody in. Das, P. K., *et al.* .....(A) 462
—, detection of, using human and equine C_1q, in leprosy patients. Kliemann, T. A. E., *et al.* .....(A) 351

Immunity,
significance of . . . in leprosy. Bjune, G. .....(A) 469

Immunity, cell-mediated (CMI),
evaluation in mice, studies on immune response in *M. lepraemurium*. Navalkar, R. G., *et al.* .....(A) 476
in a group of leprosy patients, leukocyte migration inhibition test. Garcia González, J., *et al.* .....(A) 93
role of macrophages in defective, factors from macrophages affecting protein synthesis and lymphocyte transformation. SALGAME, P. R., *et al.* .....(O) 172
—, macrophage and lymphocyte interaction. BIRDI, T. J., *et al.* .....(O) 178

Immunodeficiency,
possible origin, in Virchowian hanseniasis. Fliess, E. L. .....(A) 351

Immunoelectrophoresis,
crossed, with intermediate gel, assay for antibodies in leprosy sera reacting with RNP using. STONER, G. L., *et al.* .....(O) 247

Immunofluorescence,
test for detection of antibodies to *M. tuberculosis*. Mahfouz, M. O., *et al.* .....(A) 363

Immunoglobulin(s),
antibodies against *M. leprae* in . . . G and M, in pregnant and nonpregnant lepromatous leprosy sera. Melsom, R. and Duncan, M. E. .....(A) 472
concentration, in mothers with leprosy and healthy controls and their babies, at birth. Melsom, R., *et al.* .....(A) 352
dermal . . . deposits, circulating antibodies to connective tissue microfibrils and, in leprosy. Lindner, E., *et al.* .....(A) 94
humoral factors (. . . and complement), *in vitro* synthesis of, in lesional skin of leprosy patients. Lai A. Fat, R. F. M., *et al.* .....(A) 93

Immunology,
and the therapeutics of leprosy. Bullock, W. E. .....(A) 82
differences among active, inactive and relapsed patients, in leprosy. Koseki, M., *et al.* .....(A) 500
games parasites play, how parasites evade surveillance. Bloom, B. R. .....(A) 239
indirect immunoperoxidase technique in human leprosy. Alonsó, J. M., *et al.* .....(A) 92
"N-Factor/Anergic Margin" or resistance/susceptibility to hanseniasis. Rotberg, A. (A) 239
rabbit red blood cell rosette formation method, thymectomized guinea pigs, immunopharmacological studies. Tsutsumi, S., *et al.* .....(A) 499
thoughts on, of leprosy. GOIHMAN-YAHR, M. .....(E) 435

Immunoprophylaxis,
Chagas' disease, potential for. .....(A) 240

Immunostimulation,
leprosy treatment by association of chemotherapy and. Saint-André, P., *et al.* .....(A) 344

Indeterminate leprosy,
changes in . . . and lepromatous leprosy patients and Mitsuda-negative contacts, after inoculation of *M. leprae* and BCG mixture. Covit, J., *et al.* .....(A) 93
immunological studies in patients with. Fliess, E. L., *et al.* .....(A) 93
location of . . . form in classification of leprosy. Consigli, C. A. .....(A) 88

India,
Bombay Leprosy Project issues 1978 annual report. ....(N) 74
Eighth Workshop on Leprosy held by The Foundation for Medical Research. ....(N) 214
XI Biennial Conference of Indian Association of Leprologists meets in Madras. Gordon, G. ....(N) 214
Emmaus Referral Hospital and Leprosy Project. ....(N) 213
Gandhi Memorial Leprosy Foundation announces courses. ....(N) 75
GLRA leprosy control work in Bombay. ....(N) 213
HLA—A, B and C antigens, in South Indian leprosy families. Wolf, E., *et al.* ....(A) 478
Maharashtra, integration of leprosy control and general services in. Kapoor, P., *et al.* ....(A) 83
Presidential address, Indian Association of Dermatologists, Venereologists and Leprologists. Bedi, B. M. S. ....(A) 458
Schieffelin Leprosy Training and Research Centre, 1980 schedule of courses. ....(N) 75
—, 1981 schedule of courses. ....(N) 448
—, opens new facility. ....(N) 447
secondary dapsone resistance, prevalence, in Gudiyattam Taluk. BALRAJ, V., *et al.* ....(O) 397
seven year study results on BCG released. ....(N) 213
Tamil Nadu, antigenic subtypes of HB_sAg, in patients with liver disease and leprosy in. Thyagarajan, S. P., *et al.* ....(A) 468
trial of BCG vaccines, for tuberculosis prevention, in South. ....(A) 242
tuberculosis in. Nagpaul, D. R. ....(A) 105
WHO, short term consultants in South. ....(N) 449
—, workshop held at JIPMER. ....(N) 214

INH,
cholestatic hepatitis during treatment with . . . and rifampin. Poupon, R. Y., *et al.* ...(A) 464

INTERNATIONAL JOURNAL OF LEPROSY,
acknowledgement. ....(—) 107
....(—) 245
....(—) 369
....(—) 524
available through UMI Serials Program. Gordon, G. ....(N) 338
information requested from national leprosy associations for. HASTINGS, R. C. ....(E) 439
reviewers, list of. ....(—) 453
statement of financial condition. ....(—) 365
statement of ownership, management and circulation. ....(—) 556

International Leprosy Association,
new members approved. ....(N) 78
organization and membership. ....(—) 510
statement of financial condition. ....(—) 368

Iridocyclitis,
lepromatous, diagnosed by anterior chamber paracentesis. Michelson, J. B., *et al.* ...(A) 89

Isonicotinic acid,
hydrazide, isolation culture of seven strains of *M. lepraemurium* and, or rifampin resistant Hawaiian strain. Mori, T. and Kohsaka, K. ....(A) 232

Italy,
Health Cooperation Papers, published in. Nunzi, E., ed. ....(B) 340

Japan,
Dr. S. G. Browne honored. Gordon, G. ....(N) 76
Dr. W. F. Kirchheimer speaks. Gordon, G. ....(N) 215
immunogenetic background of leprosy patients in, by HLA and serum protein allotypes. Sugiyama, K., *et al.* ....(A) 502
Japan Shipbuilding Industry Foundation contributes to WHO. ....(N) 214
Miyako Islands, FLA-ABS test in three villages of, immuno-epidemiological studies on subclinical infection with *M. leprae*. Abe, M., *et al.* ....(A) 500
XVI International Congress of Dermatology announced. ....(N) 76

Kala-azar,
immunological responses in Indian. Aikat, B. K., *et al.* .....(A) 238

Kenya,
short-course (6 month) chemotherapy regimens for pulmonary tuberculosis in nomads in. Aluoch, J. A. .....(A) 239

Korea,
chemotherapeutic trials on leprosy in, review. Lew, J. .....(A) 463
prevalence of autoantibodies in . . . leprosy patients. Moon, K. C. .....(A) 231
Wilson Leprosy Center & Rehabilitation Hospital issues 1979 annual report. .....(N) 334

Laviron, Paul,
obituary. Sansarricq, H. .....(Ob) 66

Leishmanin (Montenegro reaction),
transfer of delayed hysensitivity to. Mendes, E. .....(A) 105

Lepromatous leprosy,
—. Busch, S. and Korting, G. W. .....(A) 346
activity and effective serum level of repository sulfones (DADDS) in. Anand, L. C. and Rathore, B. S. .....(A) 85
and contact dermatitis. Jerez, J., *et al.* .....(A) 466
Australia antigen in, in Egypt. Sheri, S., *et al.* .....(A) 229
extensive skin necrosis in, in reactive exacerbation. Bourgeois-Droin, Ch., *et al.* .....(A) 87
genetic hypothesis for susceptibility to. Smith, D. G. .....(A) 101
histopathology of the spleen in. Rea, T. H., *et al.* .....(O) 285
immunological changes in indeterminate and . . . patients and Mitsuda-negative contacts, after inoculation of *M. leprae* and BCG mixture. Convit, J., *et al.* .....(A) 93
in situ activation of suppressor T-cells in . . . patients. Mehra, V., *et al.* .....(A) 502
in the head-neck region. Koch, U., *et al.* .....(A) 347
in vivo effects of propranolol on some cellular and humoral immune functions in a group of patients with. Anderson, R., *et al.* .....(A) 469
infiltration of lower abdominal skin in. Mahapatra, S. B. .....(A) 467
intermittent rifampin therapy in. Girdhar, B. K., *et al.* .....(A) 343
laparoscopic aspects of. Herrerias, J. M., *et al.* .....(A) 466
LH, FSH responses to GnRH in. Dash, R. J., *et al.* .....(A) 88
model of Schwann cell pathology and lysosomal activity. Dastur, D. K. and Porwal, G. L. .....(A) 470
paranasal sinuses in. Barton, R. P. E. and McDougall, A. C. .....(A) 226
—, radiologic changes in. Barton, R. P. E. .....(A) 226
PBL transformation to testis in patients with. Wall, J. R., *et al.* .....(A) 95
phagocytosis in leprosy, defective adhesive and endocytic abilities of circulating leukocytes in. Rojas-Espinosa, O., *et al.* .....(O) 159
reduction of subset of T cells bearing Fc receptors for IgG in. Singh, S. and Nath, I. .....(A) 473
role of macrophages in defective cell-mediated immunity in, factor(s) from macrophages affecting protein synthesis and lymphocyte transformation. Salgame, P. R., *et al.* .....(O) 172
—, macrophage and lymphocyte interaction. Birdi, T. J., *et al.* .....(O) 178
scrotal biopsy in subsided cases of. Ramu, G. and Desikan, K. V. .....(A) 96

Lepromin,
armadillo, double blind trials to determine late reactivity of leprosy patients and unaffected persons to, compared to human. Bechelli, L. M., *et al.* .....(O) 126
—, leukocyte inhibiting factor (LIF) production from human lymphocytes of healthy donors stimulated by. Fumarola, D., *et al.* .....(A) 470
-induced suppressor cells in patients with leprosy. Mehra, V., *et al.* .....(A) 94
lymphocyte sensitization to, in patients with polar types of leprosy. Podoplelov, I. I. and Selezneva, S. P. .....(A) 472
nature and familial characteristics of . . . sensitivity. Kundu, S. K., *et al.* .....(A) 235

Leprosy,
—. Bryceson, A. and Pfaltzgraff, R. E. .....(B) 339

—. Dharmendra. ....(B) 339
—. Grove, D. I. ....(A) 459
—. Klingmüller, G. ....(B) 340
a modern enigma. Beson, C. A. ....(A) 342
and art in South China. SKINSNES, O. K. ....(C) 71
— fertility. Smith, D. G. and Guinto, R. S. ....(A) 91
— pregnancy. Coudert, J., *et al.* ....(A) 227
— the nervous system. Hentschel, B. ....(A) 466
autochthonous. Godeau, P., *et al.* ....(A) 235
child. El-Zawahry, M. and El-Zawahry, K. ....(A) 234
circulating complexes in, studied by platelet aggregation test. Wager, O., *et al.* ....(A) 95
Clinical Leprosy. Sehgal, V. N. ....(B) 454
cough reflex in. Malik, S. K., *et al.* ....(A) 89
duration of treatment for "disease arrest" of non-lepromatous, relapse rate. Ekambaram, V. ....(A) 234
frequency of, in a university hospital. Figueiredo, A. A. and Sudo, L. ....(A) 358
in a Vietnamese adoptee. Lauer, B. A., *et al.* ....(A) 347
in archeologically recovered bamboo book in China. SKINSNES, O. K. ....(C) 333
in Indochinese refugees. Bourne, A. J., *et al.* ....(A) 465
in the Central African Empire. Vinet, J. ....(A) 101
indigenous, in Sicily. Guarneri, G., *et al.* ....(A) 476
kidney transplantation in. Mocelin, A. J., *et al.* ....(A) 89
malnutrition and. Edelman, R. ....(A) 88
neural. Carrillo Casaux, D. and Carrillo Montesinos, J. M. ....(A) 96
pathological manifestations of. Kasili, E. G., *et al.* ....(A) 231
pathology of spinal cord in. Koya, G. and Arakawa, I. ....(A) 467
platelet adhesiveness in. Parvez, M., *et al.* ....(A) 94
relation of vascular and osseous changes in. Johnson, A. C., *et al.* ....(A) 466
research, recent developments in. Kansky, A. ....(A) 342
serum calcium and magnesium in. Nigam, P., *et al.* ....(A) 468
— lipid profile in. Sritharan, V., *et al.* ....(A) 230
Society and Leprosy. Mutatkar, R. K. ....(B) 454
strategy of early detection of infectious, role of medical personnel. Kapoor, P. and Yellapurkar, M. V. ....(A) 235
tuberculosis and. Pattyn, S. R. ....(A) 83
—. Sutherland, I. ....(A) 84

The Leprosy Study Centre,
ceases operations. ....(N) 450

Lesion(s),
cutaneous, due to *M. kansasii*. Bolivar, R., *et al.* ....(A) 240
lichen planus-like, caused by thiacetazone. Mani, M. Z., *et al.* ....(A) 344
ocular, in leprosy. Carrica, A., *et al.* ....(A) 226
of the index branch of the radical cutaneous nerve, in early leprosy. Shetty, V. P., *et al.* ....(A) 354
pathogenesis of the skin, application of periodic acid-carbol pararosanilin, periodic acid-methenamine silver stains. Harada, K. and Kasai, T. ....(A) 506
sciatic nerve, in *M. leprae* inoculated mice, nerve conduction velocity correlates. Shetty, V. P., *et al.* ....(A) 354
skin, *in vitro* synthesis of anti-mycobacterial antibodies in biopsies from, of leprosy patients. Lai A. Fat, R. F. M., *et al.* ....(A) 352

Leukocytes,
defective adhesive and endocytic abilities of circulating, phagocytosis in leprosy, in lepromatous leprosy. ROJAS-ESPINOSA, O., *et al.* ....(O) 159

Lewis rat(s),
combined rifampin and dapsone chemotherapy of *M. leprae* infection of the neonatally thymectomized. FIELDSTEEL, A. H. and LEVY, L. ....(O) 267
neonatally thymectomized, compared to congenitally athymic nude rat, with respect to *M. leprae* infection. Fieldsteel, A. H., *et al.* ....(A) 491

Liver,
function tests, in tuberculoid leprosy. Koranne, R. V., *et al.* .....(A) 347

Long, Esmond Ray,
obituary. Binford, C. H. .....(Ob) 322

Lucio's phenomenon,
—. Pursley, T. V., *et al.* .....(A) 229

Lymph node(s),
bacteriological and morphological indices in, by needle aspiration. Kaur, S., *et al.* ...(A) 346
involvement, in tuberculoid leprosy. Koranne, R. V., *et al.* .....(A) 231

Lymphocyte(s),
antibiotics and suppression of . . . function, *in vitro*. Banck, G. and Forsgren, A. .....(A) 85
human, leukocyte inhibiting factor (LIF) production from, of healthy donors, stimulated by armadillo lepromin. Fumarola, D., *et al.* .....(A) 470
mixed . . . reaction, factors contributing to impairment, in leprosy. Han, S. H., *et al.* (A) 471
responses, variation of *in vitro*, to *M. leprae* antigen, in borderline tuberculoid leprosy patients. BJUNE, G. .....(O) 30
sensitization, to lepromin, in patients with polar types of leprosy. Podoplelov, I. I. and Selezneva, S. P. .....(A) 472
stimulation, *in vitro*, simultaneously with *M. leprae* antigens and phytohemagglutinin, in leprosy. Bjune, G. .....(A) 350
T and B, content of, in blood of patients with polar types of leprosy. Selezneva, S. P. and Podoplelov, I. I. .....(A) 232
—, dynamics of, in process of infection, quantitative cytochemical data. Trofimov, G. K., *et al.* .....(A) 106

Lymphocytotoxins,
in leprosy, in asymptomatic hepatitis B virus infection. Serjeantson, S. and Dry, P. (A) 354

Lysosome(s),
. . . contrasts in the immunological polar dichotomy of leprosy. Skinsnes, O. K. .....(A) 355

Macrophage(s),
behavior, to *M. leprae*, tissue culture study. Veliath, A. J., *et al.* .....(A) 94
cellular immunity and phagocytic activity of, in 63 cases of leprosy. .....(A) 470
defective T cell-, interaction in leprosy. Hirschberg, H. and Bergh, O. .....(A) 471
function, in severe protein energy malnutrition. Bhaskaram, P. .....(A) 479
of *M. leprae* inoculated armadillos, ultrastructural features of multiplication of leprosy bacilli. Fukunishi, Y., *et al.* .....(A) 494
role, in defective cell-mediated immunity, in lepromatous leprosy, factors from . . . affecting protein synthesis. SALGAME, P. R., *et al.* .....(O) 172
—, —, —, . . . and lymphocyte interaction. BIRDI, T. J., *et al.* .....(O) 178

Madagascar,
Bibliographie Analytique des Travaux de L'Institut Pasteur de Madagascar—1898–1978. Coulanges, P. and Coulanges, M. .....(A) 339

Malaria,
leprosy, filariasis and, causes of secondary amyloidosis, in the tropics. McAdam, K. P. W. J. .....(A) 347

Malaysia,
Fourth Regional Conference on Dermatology in. .....(N) 76
personalities in leprosy work in. Pettit, J. M. S. .....(N) 76
status of Sungei Buloh Leprosarium. Pettit, J. M. S. .....(N) 76
unusual reaction to intramuscular sulfone, in two leprosy patients in. LAING, A. B. G. .....(C) 70

Mali,
The Marchoux Institute. Saint André, P. .....(A) 343

Malnutrition,
and leprosy. Edelman, R. .....(A) 88

Mangabey monkey (*Cercocebus* sp.),
naturally acquired leprosy in. Meyers, W. M., *et al.* ....(A) 495

Martinique and Guadeloupe,
IV Congrès de Léprologie meets in. ....(N) 215
incidence of leprosy in. Argellies, J. L. ....(A) 98

Mental illness,
psychiatric disturbances in leprosy patients, epidemiological study. KUMAR, J. H. RANJIT and VERGHESE, A. ....(O) 431

Mexico,
XXXIII General Assembly of the Mexican Association against Leprosy elects officers. ....(N) 335

Mice,
does *M. leprae* behave as an intracellular parasite in? Akiyama, T. and Yamaura, N. ....(A) 503
suppressor T cells induced with mycobacterial infection in. Tokunaga, T. and Nakamura, R. M. ....(A) 503

Microbiology,
atypical mycobacteria, isolated from human sources, in Rio de Janeiro, bacteriological study and drug susceptibility test. Fonseca, L. de S. and Gontijo Filho, P. P. ....(A) 104
—, —, —, preliminary identification of colony morphologies. Fonseca, L. de S. and Gontijo Filho, P. P. ....(A) 104
identification problems of strain 0122. COCITO, C. and DELVILLE, J. ....(C) 442
of human origin, isolated in 1975–1976, in Bobo-Dioulasso (Upper Volta). Rey, J. L. and Villon, A. ....(A) 106

Minocycline,
in vitro antimycobacterial activity of. Tsukamura, M. ....(A) 363

Monocyte(s),
peripheral blood . . . function, in leprosy patients. MASUDA, A. and SCHEINBERG, M. A. ....(O) 254

Morphological Index (MI),
do the average bacterial and . . . indices reflect the patients' true condition? WARNDORFF, T. ....(C) 441

Mucosa,
nasal, borderline tuberculoid leprosy with a "lepromatous" nodule of. Barton, R. P. E., *et al.* ....(A) 345

Muscle,
soleus, Hoffmann reflex of. Sebille, A. ....(A) 349
striated, in four categories of leprosy, fine structural changes. DASTUR, D. K. and DAVER, S. M. ....(O) 149
—, —, histology and histochemistry. DAVER, S. M., *et al.* ....(O) 140

Mycobacterium bovis,
BCG, *M. lepraemurium,* effect of bases of nucleic acid on growth of. Cheng, Y. T. (A) 507

Mycobacterium kansasii,
cutaneous lesions due to. Bolivar, R., *et al.* ....(A) 240

***Mycobacterium komossense* sp. nov.,**
—. Kazda, J. and Müller, K. ....(A) 480

Mycobacterium leprae,
adjuvant immunotherapy on infection with, and *M. marinum,* effects. Krahenbuhl, J. L., *et al.* ....(A) 504
antigenic analysis of. Closs, O., *et al.* ....(A) 350
— evaluation of *M. vaccae* in relation to. NAVALKAR, R. G., *et al.* ....(O) 388
antigens and phytohaemagglutinin, *in vitro* lymphocyte stimulation with. Bjune, G. ....(A) 350
armadillo-derived, multiplication of acid-fast bacilli in nude mice inoculated with. Hastings, R. C., *et al.* ....(A) 490

attempt at *in vitro* cultivation, 23 positive cultures from 13 leprosy cases. Cao, S. N., *et al.* ....(A) 475
behavior of macrophages to, tissue culture study. Veliath, A. J., *et al.* ....(A) 94
biochemical alteration in cells following phagocytosis of. MAHADEVAN, P. R. and ANTIA, N. H. ....(O) 167
characterization of . . . "specific" antigens. Gillis, T. P. and Buchanan, T. M. ....(A) 505
combined rifampin and dapsone chemotherapy of . . . infection, of neonatally thymectomized Lewis rat. FIELDSTEEL, A. H. and LEVY, L. ....(O) 267
cultivation of, in cell culture, attempts. Matsuo, Y. ....(A) 498
— requirements for *Treponema pallidum*, . . . , other microbial and mammalian microaerophilic cells. Stevens, K. M. ....(A) 233
demonstration of antibodies against, both in IgG and IgM, in sera from pregnant and non-pregnant lepromatous leprosy patients. Melson, R. and Duncan, M. E. ....(A) 472
detection of antigen in *Nocardia caviae* cross-reacting with mycobacterial antigen No. 21 in, lepromatous leprosy serum pool used as antibody reagent. BJORVATN, B. and KRONVALL, G. ....(O) 260
does . . . behave as an intracellular parasite in mice? Akiyama, T. and Yamaura, N. ....(A) 503
effects of soluble starch lecithin and vitamins on *in vitro* growth of *M. lepraemurium* and. Nakamura, M. ....(A) 507
evidence for species specific lipid antigens in. BRENNAN, P. J. and BARROW, W. W. ....(O) 382
fluorescent leprosy antibody absorption (FLA-ABS) test for detecting subclinical infection with. ABE, M., *et al.* ....(O) 109
foot pad enlargement as a measure of induced immunity to. SHEPARD, C. C., *et al.* (O) 371
freezing and storage in liquid nitrogen on viability and growth of, effect. Colston, M. J. and Hilson, G. R. F. ....(A) 475
innoculation of mixture of . . . and BCG, immunological changes in indeterminate and lepromatous leprosy patients, Mitsuda-negative contacts after. Convit, J., *et al.* ...(A) 93
metabolic inhibitors of host-tissue origin in. Prabhakaran, K., *et al.* ....(A) 96
microscopic counts carried out on, and *M. tuberculosis* suspension, three staining procedures compared. COLLINS, F. M., *et al.* ....(O) 402
neonatally thymectomized Lewis rat (NTLR) compared to congenitally athymic nude rat with respect to infection with. Fieldsteel, A. H., *et al.* ....(A) 491
neural predilection of, in leprosy. Stoner, G. L. ....(A) 94
purification procedures on viability of, effect. PRABHAKARAN, K., *et al.* ....(C) 330
reply to Dr. Bergel's letter to the editor. SHEPARD, C. C. ....(C) 68
Shepard's method of inoculation of, in foot pads of mice, twenty years after. BERGEL, M. ....(C) 67
studied in tissue culture. Nomaguchi, H., *et al.* ....(A) 508
variation of *in vitro* lymphocyte responses to . . . antigen, in borderline tuberculoid leprosy patients. BJUNE, G. ....(O) 30
viability of, effect of ultraviolet rays and sunlight. Wang, H. Y. and Huang, H. S. ...(A) 475

***Mycobacterium lepraemurium*,**
active or passive acquired resistance after . . . infection, in C57BL/6 and C3H/HeN mice. Lagrange, P. H. ....(A) 97
effect of bases of nucleic acid on growth of *M. bovis*, BCG and. Cheng, Y. T. ....(A) 507
— — soluble starch lecithin and vitamins, on *in vitro* growth of . . . and *M. leprae*. Nakamura, M. ....(A) 507
growth and drug sensitivity of, by tissue culture applying monolayer and agar suspension technique. NOMAGUCHI, H., *et al.* ....(O) 277
immune response to, cell-mediated immune response in mice evaluated. Navalkar, R. G., *et al.* ....(A) 476
influence of BCG vaccination on murine leprosy in C57BL/6 and C3H mice. Lagrange, P. H. and Hurtrel, B. ....(A) 233
in vitro cultivation and characterization of. PATTYN, S. R. and PORTAELS, F. ....(O) 7
isolation culture of seven strains of . . . and isonicotinic acid hydrazide or rifampin resistant Hawaiian strain. Mori, T. and Kohsaka, K. ....(A) 232
pathogenicity of cultivated murine leprosy bacilli of Hawaiian-Ogawa strain in mice,

visceral lesions in mice produced by intraperitoneal infection. Kawaguchi, Y., *et al.* ....(A) 96
serum protein fraction of mice inoculated with drug resistant murine leprosy bacilli. Nakagawa, K., *et al.* ....(A) 234

***Mycobacterium marinum*,**
effects of adjuvant immunotherapy on infection with *M. leprae* and. Krahenbuhl, J. L., *et al.* ....(A) 504

***Mycobacterium smegmatis*,**
inhibition by ethambutol of mycolic acid transfer into the cell wall of. Takayama, K., *et al.* ....(A) 86

***Mycobacterium sphagni* sp. nov.,**
—. Kazda, J. ....(A) 479

***Mycobacterium tuberculosis*,**
comparison of plain egg medium with Löwenstein-Jensen medium in isolation of, from sputum. Venkataraman, P., *et al.* ....(A) 243
immunofluorescence test for detection of antibodies to. Mahfouz, M. O., *et al.* ....(A) 363
microscopic counts carried out on *M. leprae* and . . . suspensions, three staining procedures. COLLINS, F. M., *et al.* ....(O) 402

***Mycobacterium vaccae*,**
antigenic evaluation of, in relation to *M. leprae*. NAVALKAR, R. G., *et al.* ....(O) 388

Mycolic acid(s),
analysis, in mycobacteria isolated from lesions of armadillos with naturally acquired leprosy-like disease and experimental armadillo leprosy. Kusaka, T., *et al.* ....(A) 494
transfer, inhibition by ethambutol of, into *M. smegmatis* cell wall. Takayama, K., *et al.* ....(A) 86

Nepal,
Kathmandu workshop on leprosy held. Browne, S. G. ....(N) 77
leprosy in peripheral nerves, histopathological findings in 119 untreated patients in. Pedley, J. C., *et al.* ....(A) 353

Nephritis,
rifampin-induced tubulo-interstitial. Min, K. U., *et al.* ....(A) 223

Nerve(s),
calcification caused by leprosy in Northern Territory Aboriginals. Bateson, E. M. and Hargrave, J. C. ....(A) 87
collagen of permanently damaged, in human leprosy. JUNQUEIRA, L. C. U., *et al.* ...(O) 291
cubital, motor transmission velocity of, in patients with lepra reaction, 30-year observations during thalidomide treatment. Sheskin, J. and Yaar, I. ....(A) 91
electrophysiological evidence for motor unit impairment during leprosy treatment. Linois, H. and Sebille, A. ....(A) 362
evolution of damage in leprosy. Antia, N. H., *et al.* ....(A) 350
greater auricular, in presumably non-leprous British soldiers. Lynch, P. and Johnston, J. H. ....(A) 467
peripheral, involvement in leprosy, neuropathological study of autopsy cases. Mukoyama, M. and Sasaki, N. ....(A) 472
—, leprosy in, histopathological findings in 119 untreated patients in Nepal. Pedley, J. C., *et al.* ....(A) 353
permanent damage, in reversal reaction, DDS 100 mg daily preventing. VAN DER MEULEN, J. ....(C) 208
radial cutaneous, lesions of index branch of, in early leprosy. Shetty, V. P., *et al.* ...(A) 354
—, observations of index branch of, in leprosy contacts. Shetty, V. P., *et al.* ....(A) 354
reply to Dr. Van der Meulen's letter to the editor. NAAFS, B. ....(C) 209
sciatic lesions, in *M. leprae* inoculated mice, nerve conduction velocity correlates. Shetty, V. P., *et al.* ....(A) 354
thickened, in a leprosy endermic region, clinical and histological study. Srinivas, H. V., *et al.* ....(A) 355

—, —, ultrastructural and tease fiber study. Mehta, L. N., *et al.* ....(A) 352
ulnar, decompression by medial epicondylectomy of the humerus. Oommen, P. K. ...(A) 103
—, surgery on, in leprosy. Palande, D. D. ....(A) 363

Nerve culture,
organized, DNA synthesis in Schwann cells, in presence of *M. leprae*. MUKHERJEE, R., *et al.* ....(O) 189
—, technique to study effect of *M. leprae* infection. MUKHERJEE, R., *et al.* ....(O) 183

Neuritis,
chemotherapy of, in leprosy. Carayon, A. ....(A) 85
microangiopathic, in leprosy. Carayon, A. ....(A) 92
new approach to relief of pain in. Mehta, J. M., *et al.* ....(A) 228
segmental necrotizing granulomatous, in leprosy. CHANDI, S. M., *et al.* ....(O) 41

Neuropathy,
somatosensory and autonomic, only manifestation of long standing leprosy. Gadoth, N., *et al.* ....(A) 227

***Nocardia caviae*,**
detection of antigen in, cross-reacting with mycobacterial antigen No. 21 in *M. leprae*, using a lepromatous leprosy serum pool as antibody reagent. BJORVATN, B. and KRONVALL, G. ....(O) 260

Norway,
leprosy in, epidemiological study based on national patient registry. Irgens, L. M. ...(A) 358
medical researcher position available at AHRI. ....(N) 449

Norwegian scabies,
what is your diagnosis? ....(A) 92

Nude mice,
as an experimental lepromatous leprosy model, lepromatoid lesions in mystacial vibrissae located site of injection. Nakamura, K. and Yogi, Y. ....(A) 490
effect of DDS on, experimentally infected with *M. leprae*. Kohsaka, K., *et al.* ....(A) 496
multiplication of acid-fast bacilli in, inoculated with armadillo-derived *M. leprae*. Hastings, R. C., *et al.* ....(A) 490

Obituaries,
Gilbert, Maurice. Contreras Dueñas, F. ....(Ob) 443
Laviron, Paul. Sansarricq, H. ....(Ob) 66
Long, Esmond Ray. Binford, C. H. ....(Ob) 322
Prast, Dr. Javier Guillen. Contreras Dueñas, F. ....(Ob) 443
Prieto, José Gay. Contreras Dueñas, F. ....(Ob) 206
Rodríguez, José N. Guinto, R. S. ....(Ob) 327

o-Diphenoloxidase,
concentrations in leprosy. Reza, K., *et al.* ....(A) 90

Pakistan,
Dr. Ruth Pfau honored by government. ....(N) 449

Papua New Guinea,
amyloid fibril proteins found in. Anders, R. F. ....(A) 349

Paraguay,
report on armadillo studies in. Gordon, G. ....(N) 215
tuberculosis/leprosy eradication project in. ....(N) 74

Pfau, Dr. Ruth,
personal. ....(N) 449

Phagocytosis,
in leprosy, defective adhesive and endocytic abilities of circulating leukocytes in lepromatous leprosy. ROJAS-ESPINOSA, O., *et al.* ....(O) 159

Philippines,
Tenth International Congress on Tropical Medicine and Malaria meets in. ....(N) 335

Phlebitis,
leprous. MUKHERJEE, A., *et al.* ....(O) 48

Physical therapy,
Physical Therapy in Leprosy for Paramedicals. Kelly, E. D. ....(B) 219

Phytohemagglutinin,
M. leprae antigens and, simultaneous stimulation with. Bjune, G. ....(A) 350

Platelet(s),
adhesiveness, in leprosy. Parvez, M., *et al.* ....(A) 94

Prast, Dr. Javier Guillen,
obituary. Contreras Dueñas, F. ....(Ob) 443

Pregnancy,
leprosy and. Coudert, J., *et al.* ....(A) 227

Prieto, José Gay,
obituary. Contreras Dueñas, F. ....(Ob) 206

Prurigo nodularis,
treatment, with thalidomide. van den Broek, H. ....(A) 363

Psoriasis,
suppressor cell function in. Sauder, D. N., *et al.* ....(A) 241

Reaction,
lepra, evaluation of thalidomide derivatives in. Sheskin, J. ....(A) 86
—, motor transmission velocity of the orbital nerves in patients with. Sheskin, J. and Yaar, I. ....(A) 91
—, treatment of steroid dependent cases of recurrent, with combination of thalidomide and clofazimine. Ramu, G. and Girdhar, A. ....(A) 229
reply to Dr. van der Meulen's letter to the editor. NAAFS, B. ....(C) 209
reversal, DDS 100 mg daily preventing permanent nerve damage in. VAN DER MEULEN, J. ....(C) 208

Rehabilitation International,
Third European Conference of, planned in Austria. ....(N) 446

Renal disease,
acute renal insufficiency caused by rifampin. Rossi, E. and Montagna, G. ....(A) 86
complications, frequency of sulfone resistance, results of long-term treatment. Terencio de las Aguas, J. ....(A) 86
renal amyloidosis in Blacks. Gold, C. H. ....(A) 89

Rifampin,
acute renal insufficiency caused by. Rossi, E. and Montagna, G. ....(A) 86
adverse reactions to. Girling, D. J. and Hitze, K. L. ....(A) 344
and dapsone, combination, chemotherapy of *M. leprae* infection of neonatally thymectomized Lewis rat. FIELDSTEEL, A. H. and LEVY, L. ....(O) 267
— vitamin D metabolism. Brodie, M. J., *et al.* ....(A) 461
cholestatic hepatitis during treatment with INH and. Poupon, R. Y., *et al.* ....(A) 464
clinically equivalent doses of dapsone and, on antibody production and delayed-type hypersensitivity, to sheep red blood cells, in mice. Nagata, Y. and Ito, T. ....(A) 498
comparative study of variable averages of bacilloscopic and morphologic indexes in virchowian hanseniasis patients treated with, and DDS. Belda, W., *et al.* ....(A) 461
effect of, on the immune response in mice. Bellahsene, A. and Forsgren, A. ....(A) 222
high performance liquid chromotography method for simultaneous analysis of DDS, . . . , B663 and main metabolites. Tsutsumi, S. and Gidoh, M. ....(A) 496
in vitro effect of, on serum bilirubin determinations. Meisel, S., *et al.* ....(A) 464
-induced tubulo-interstitial nephritis. Min, K. U., *et al.* ....(A) 223
intermittent therapy, in lepromatous leprosy. Girdhar, B. K., *et al.* ....(A) 343
pseudomembranous colitis and. Acocella, G. and Arioli, V. ....(A) 343
—. Fournier, G., *et al.* ....(A) 222
"pulsed" . . . therapy, in leprosy. Girdhar, B. K. and Desikan, K. V. ....(A) 223

seven years of leprosy treatment with. Terencio de las Aguas, J., *et al.* ....(A) 464
single dose of 1.5 gm of, with prolonged sulfone treatment, in leprosy. Languillon, J. ....(A) 85

Rodríguez, José N.
obituary. Guinto, R. S. ....(Ob) 327

Rubino test,
platelet aggregation test and, circulating complexes studied by platelet aggregation test, in 135 leprosy patients. Wager, O., *et al.* ....(A) 95

Saudi Arabia,
epidemiological study of leprosy and leprosy care in. Sebai, Z. A. ....(A) 477

Seychelles,
leprosy in the. Grainger, C. R. ....(A) 358

Sinus(es),
paranasal, in lepromatous leprosy. Barton, R. P. E. and McDougall, A. C. ....(A) 226
—, —, radiological changes. Barton, R. P. E. ....(A) 226

Skin,
abdominal, infiltration of lower, in lepromatous leprosy. Mahapatra, S. B. ....(A) 467
biopsies, lactate dehydrogenase zymograms of, in leprosy patients. SAOJI, A. M. ....(O) 426
lesional, *in vitro* synthesis of humoral factors, in leprosy patients. Lai A. Fat, R. F. M., *et al.* ....(A) 93
necrosis, extensive, in lepromatous leprosy in reactive exacerbation. Bourgeois-Droin, Ch., *et al.* ....(A) 87
slit- . . . smears, selection of sites for. Ahmed, H. A., *et al.* ....(A) 225
thermal sensitivity of, instrument to investigate. de Castro, I. M. ....(A) 346

Social and human aspects of leprosy,
Brazilian Phase III of prevention of hanseniasis. Rotberg, A. ....(A) 460
causes of unemployment among agricultural laborers with leprosy. Kuppusamy, P., *et al.* ....(A) 103
employer acceptance of the HD patient and other handicapped persons. FRIST, T. F. ....(O) 303
integration of handicapped persons with leprosy into the community. Lew, J. ....(A) 459
medical certification of leprosy patients and reservation in service for the physically handicapped, including persons with leprosy. MEHTA, J. M. ....(C) 332
Society and Leprosy. Mutatkar, R. K. ....(B) 454
survey of social situation of patients at JALMA Leprosy Centre, Agra, India, medical aspects. Osaka, R. ....(A) 236
Workshop on Human Aspects in the Treatment of Leprosy Patients. ....(B) 80

South Africa,
association of tuberculosis and leprosy in. Gatner, E. M. S., *et al.* ....(A) 346
genetic markers and leprosy in, erythrocyte enzyme polymorphisms. Hitzeroth, H. W., *et al.* ....(A) 99

Spain,
two leprosy courses held at Fontilles. ....(N) 215

Spleen,
histopathology, in a lepromatous leprosy patient. REA, T. H., *et al.* ....(O) 285

Stain(s),
Harada's staining method for leprosy bacilli. Harahap, M. and Nasution, A. H. ....(A) 356
periodic acid-carbol pararosanilin and periodic acid-methenamine silver, in pathogenesis of skin lesion, in leprosy. Harada, K. and Kasai, T. ....(A) 506
soluble blue as a counterstain in the Ziehl-Neelsen procedure. WHEELER, P. R. and DRAPER, P. ....(O) 15

Sulfamethazine,
acetylation phenotypes, kinetic discrimination of three. Chapron, D. J., *et al.* .....(A) 222

Sulfone(s),
activity and effective serum level of repository . . . (DADDS), in lepromatous leprosy. Anand, L. C. and Rathore, B. S. .....(A) 85
ELISA inhibition technique for demonstration of, in body fluids, specific antibody-enzyme conjugate. Huikeshoven, H., *et al.* .....(A) 223
therapy on the outliving of hanseniasis patients. Marlet, J. M. .....(A) 359
unusual reaction to intramuscular, in Malaysia, in two leprosy patients. LAING, A. B. G. .....(C) 70

Sulfone resistance,
frequency, results of long-term treatment with sulfones, renal complications. Terencio de las Aguas, J. .....(A) 86
primary, in leprosy. Jacobson, R. R. and Hastings, R. C. .....(A) 498

Sulfonemia,
hematocrit and, in leprous patients. Magna, L. A., *et al.* .....(A) 223

Surgery,
cataract, in leprosy patients. ffytche, T. J. .....(A) 237
correction of facile profile, in leprosy. Teixera, A. C. .....(A) 103
ectropion-lagophthalmos, correction of paralysis in orbital region, in leprosy. Lerner, R. D. and Margarido, L. C. .....(A) 363
in leprosy, after 25 years. Bourrel, P. .....(A) 362
leprosy and thumb reconstruction by opponensplasty, or phalangizing the first metacarpal. Brown, H. and Getty, P. .....(A) 102
ulnar nerve, decompression by medial epicondylectomy of the humerus. Oommen, P. K. .....(A) 103
—, in leprosy. Palande, D. D. .....(A) 363

Switzerland,
availability of histamine chlorhydrate or phosphate (1:1000) for testing in suspected leprosy. .....(N) 216
chemotherapy of leprosy discussed. .....(N) 77
—. .....(N) 335

Teaching and training,
educational opportunities available at Carville. .....(N) 338
evaluation of interactive instructional television program, in leprosy. O'Connor, R. J. J. .....(A) 343
leprosy seminar held. .....(N) 337
of leprosy in medical schools, four and one-half hours in three years. MCDOUGALL, A. C. and WEDDELL, A. G. M. .....(C) 329
The 2nd International Workshop on Leprosy Workers in Asia. .....(B) 220

Testis,
studies on PBL transformation to, in lepromatous leprosy. Wall, J. R., *et al.* .....(A) 95

Thailand,
cellular immunity in clinically healthy children of parents with, in Northern. Nelson, K. E., *et al.* .....(A) 501
HLA antigens and leprosy in. Chiewsilp, P., *et al.* .....(A) 99
report of activities of McKean Rehabilitation Institute. .....(N) 336

Thalidomide,
and clofazimine, combination, treatment of steroid dependent cases of recurrent lepra reaction with. Ramu, G. and Girdhar, A. .....(A) 229
derivatives, in lepra reaction. Sheskin, J. .....(A) 86
in treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Mascaro, J. M., *et al.* .....(A) 105
motor transmission velocity of cubital nerves, in patients with lepra reaction treated with, 30-year observations. Sheskin, J. and Yaar, I. .....(A) 91

prurigo nodularis, treatment with. van den Broek, H. ....(A) 363
ulcerative colitis, treatment of. Waters, M. F. R., *et al.* ....(A) 86

The Netherlands,
epidemiology of leprosy in, I. Leiker, D. L. ....(A) 100
—, II. Leiker, D. L. ....(A) 100

Thiacetazone,
lichen planus-like lesions caused by. Mani, M. Z., *et al.* ....(A) 344
side-effect of. White, G. de L. ....(A) 225

Thiosemicarbazone(s),
2-acetylpyridine, inhibition of clinically significant bacterial organisms *in vitro*. Dobek, A. S., *et al.* ....(A) 462
—, new series of compounds with antileprosy activity. Morrison, N. E., *et al.* ....(A) 497

Thyroxine,
and leprosy. JOPLING, W. H. ....(C) 211

Tissue(s),
connective . . . microfibrils, and dermal immunoglobulin deposits, circulating antibodies to, in leprosy. Lindner, E., *et al.* ....(A) 94
culture, growth and drug sensitivity of *M. lepraemurium* by, applying monolayer and agar suspension technique. NOMAGUCHI, H., *et al.* ....(O) 277
—, studies on *M. leprae* in. Nomaguchi, H., *et al.* ....(A) 508
elastic . . . system, histomorphology, in skin of human hand. Enna, C. D. and Dyer, R. F. ....(A) 102
soft- . . . research, at Carville. Beach, R. B. and Thompson, D. E. ....(A) 237

Transfer factor,
for prevention of variceller-zoster infection, in childhood leukemia. Steele, R. W., *et al.* ....(A) 480

Transmission,
in man. HUANG, C. L.-H. ....(E) 309
new dimensions of understanding, priorities in leprosy control. Davey, T. F. ....(A) 357
of human leprosy bacilli, to European hedgehog. Klingmüller, G. and Sobich, E. ....(A) 97

Trautman, John R.,
personal. Gordon, G. ....(N) 217

Treatment,
irregularity, magnitude and causes. Nigam, P., *et al.* ....(A) 521
medication monitor, in . . . of tuberculosis, in developing countries. Moulding, T. ....(A) 224
risks of treating leprosy in a general hospital. MATHAI, R., *et al.* ....(O) 298

Treponema pallidum,
cultivation requirements for, and *M. leprae*, and other microbial and mammalian microaerophilic cells. Stevens, K. M. ....(A) 233

Tropical disease(s),
new policies of WHO in research to control six. de Maar, E. W. J. ....(A) 458
The in vitro *Cultivation of the Pathogens of Tropical Diseases*. ....(B) 455

Tuberculin,
test, oral BCG vaccine, tuberculosis infection, in children under five years. Dias, M. H. de P. and Hayashi, A. ....(A) 103

Tuberculoid leprosy,
aspects of, chemotherapeutic trials. Noussitou, F. ....(A) 228
borderline, with a "lepromatous" nodule of the nasal mucosa. Barton, R. P. E., *et al.* ....(A) 345
electron microscopic study of tuberculoid lesions and a proposal of subpolar. Okada, S. ....(A) 506
HLA segregation of, confirmation of DR2 marker. van Eden, W., *et al.* ....(A) 478
liver function tests in. Koranne, R. V., *et al.* ....(A) 347
lymph node involvement in. Koranne, R. V., *et al.* ....(A) 231

systemic involvement in. Singh, R. and Koranne, R. V. ....(A) 232
variation of *in vitro* lymphocyte responses to *M. leprae* antigen in borderline.
BJUNE, G. ....(O) 30

Tuberculosis,
and leprosy. Sutherland, I. ....(A) 84
—, compared. Pattyn, S. R. ....(A) 83
—, in South Africa. Gatner, E. M. S., *et al.* ....(A) 346
diagnostic potentialities of enzyme-linked immunosorbent assay in, using purified tuberculin antigen. Tandon, A., *et al.* ....(A) 480
in India. Nagpaul, D. R. ....(A) 105
medication monitor in treatment of, in developing countries. Moulding, T. ....(A) 224
monitoring regularity of drug intake in, using simple urine tests. Burkhardt, K. R. and Nel, E. E. ....(A) 479
pulmonary, cellular immunity in. Byun, H. W., *et al.* ....(A) 240
—, chemotherapy of, clinical trial of six-month and four-month regimens. ....(A) 241
—, —, controlled clinical trial of four short-course regimens. ....(A) 481
—, —, practical application of short-course (6 month) regimens, in Kenyan nomads. Aluoch, J. A. ....(A) 239
—, clinical significance of PHA skin test in lung cancer, leprosy, and. Kado, M., *et al.* ....(A) 230
research in. Williams, R., *et al.* ....(A) 243

Turkey,
leprosy training seminar held in. ....(N) 337

XII International Leprosy Congress,
details announced. ....(N) 78

Ulcer(s),
neuropathic, epithelioma cuniculatum developing in, of leprous etiology. Ochsner, P. E., *et al.* ....(A) 90
plantar, treatment of, in leprosy. Campos, M. P. ....(A) 102
sores and, epitheliomatous degeneration of, in leprosy. Rostant, M. ....(A) 90
trophic, use of Fitostimoline gauzes in leprous. Hans, G. ....(A) 346

U.S.S.R.,
development of chemotherapy of infectious diseases in. Pershin, G. N. ....(A) 344

United Kingdom,
Council for International Organizations of Medical Sciences, details on. Browne, S. G. ....(N) 450
Dr. S. G. Browne becomes Baptist leader. ....(N) 337
LEPRA announces 1980 Prize Essay Competition details. ....(N) 216
Leprosy Study Centre ceases operations. ....(N) 450
new ILA members approved. ....(N) 78
Parasite Immunology begins publication. ....(N) 78
XIII General Assembly of ILEP meets in London. Ross, W. F. ....(N) 337
XII International Leprosy Congress details announced. ....(N) 78

U.S.A.,
ALM administrative position announced. Brand, M. B. ....(N) 451
Dr. John R. Trautman promoted. Gordon, G. ....(N) 217
Dr. N. H. Antia becomes Honorary Fellow of ACS. ....(N) 78
educational opportunities available at Carville. ....(N) 338
Heiser Program for Research in Leprosy announces 1981 research possibilities. ....(N) 451
IJL available through UMI serials program. Gordon, G. ....(N) 338
National Council for International Health establishes headquarters. ....(N) 78
PAHO medical position available. ....(N) 451

U.S.-Japan Cooperative Medical Science Program,
Fifteenth Joint Leprosy Research Conference, Kagoshima, Japan, 9–11 October 1980. ....(A) 482

Upper Volta,
mycobacteria of human origin isolated in Bobo-Dioulasso, in 1975–1976. Rey, J. L. and Villon, A. .....(A) 106

Vaccination,
active, development of, in leprosy. Convit, J., *et al.* .....(A) 351
in leprosy. CONVIT, J., *et al.* .....(E) 62

Vasculitis,
necrotizing, management with colchicine. Hazen, P. G. and Beno, M. .....(A) 105

Vitamin D,
metabolism, rifampin and. Brodie, M. J., *et al.* .....(A) 461

World Health Organization (WHO),
new policies, in research on six major tropical diseases. de Maar, E. W. J. .....(A) 458
short term consultants in India. .....(N) 449

STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION

(Act of 12 August 1970; Section 3685. Title 39. United States Code)

1. Title of publication: INTERNATIONAL JOURNAL OF LEPROSY.
2. Date of filing: 24 September 1980.
3. Frequency of issue: Four times a year.
4. Location of known office of publication: USPHS Hospital, Carville, Louisiana 70721.
5. Location of the headquarters or general business offices of the publisher: INTERNATIONAL JOURNAL OF LEPROSY, 1262 Broad Street, Bloomfield, New Jersey 07003.
6. Names and addresses of publisher, editor, and managing editor: Publisher—The International Leprosy Association, 16 Bridgefield Road, Sutton, Surrey, England. Editor: Robert C. Hastings, M.D., Ph.D., USPHS Hospital, Carville, Louisiana 70721. Managing Editor: W. Felton Ross, M.B.B.S., P.O. Box 1097, Bloomfield, New Jersey 07003.
7. Owner: International Leprosy Association, Inc., 16 Bridgefield Rd., Sutton, Surrey, England.
8. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities: None.
9. For completion by nonprofit organizations authorized to mail at special rates (Section 132.122, Postal Manual): The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes have not changed during preceding 12 months.
10. Extent and nature of circulation:

A. Total no. copies printed (net press run)	1349*	1400**
B. Paid circulation		
1. Sales through dealers and carriers, street vendors, and counter sales	0	0
2. Mail subscriptions	1181	1212
C. Total paid circulation	1181	1212
D. Free distribution by mail, carrier, or other means		
1. Samples, complimentary, and other free copies	49	49
2. Copies distributed to news agents but not sold	0	0
E. Total distribution (sum of C and D)	1230	1261
F. Office use, left-over, unaccounted, spoiled after printing	119	139
G. Total (sum of E and F—should equal net press run shown in A)	1349	1400

* Average no. copies each issue during preceding 12 months.
** Actual no. of copies of single issue published nearest to filing date.

—W. Felton Ross, M.B.B.S.
Executive Officer, IJL

VOLUME 48 1980

INTERNATIONAL JOURNAL OF LEPROSY

And Other Mycobacterial Diseases

Official Organ of the
INTERNATIONAL LEPROSY ASSOCIATION
(Société Internationale de la Lèpre)
(Asociación Internacional contra la Lepra)

Contents

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

Official Organ of the International Leprosy Association

President: Prof. M. F. Lechat, Ecole de Santé Publique, Epid.-UCL 30.34, Clos Chapelle aux Champs 30, 1200 Bruxelles, Belgium

Secretary: Dr. S. G. Browne, 16 Bridgefield Road, Sutton, Surrey, SM1 2DG, England

Treasurer: Dr. W. F. Ross, 1262 Broad Street, Bloomfield, New Jersey 07003, U.S.A.

EDITORIAL AND PUBLICATION OFFICE

United States Public Health Service Hospital
Carville, Louisiana 70721
Cable Address: IJL CAR

Editor, ROBERT C. HASTINGS, Carville, Louisiana

Assistant Editor, GARY GORDON, Carville, Louisiana

BUSINESS AND CIRCULATION OFFICE

Executive Officer, W. FELTON ROSS
1262 Broad Street
Bloomfield, New Jersey 07003

BOARD OF DIRECTORS

Dr. Michel F. Lechat (President, ILA), Chairman
Dr. Stanley G. Browne (Secretary, ILA)
Dr. Wayne M. Meyers
Dr. W. Felton Ross (Treasurer, ILA)
Dr. Charles C. Shepard

CONTRIBUTING EDITORS

Argentina: Dr. J. E. Cardama (Buenos Aires)
Australia: Dr. J. C. Hargrave (Darwin)
Brazil: Dr. L. M. Bechelli (São Paulo)
France & Fr. Terr.: Dr. P. Harter (Paris)
India (North): Dr. S. Ghosh (Calcutta)
India (South): Dr. M. Christian (Karigiri)
Israel: Dr. L. Levy (Jerusalem)
Japan: Dr. M. Nishiura (Kyoto)
Malaysia & SE Asia: Dr. J. H. S. Pettit (Kuala Lumpur)
Mali: Dr. J. Languillon (Bamako)
Mexico: Dr. A. Saúl (Mexico, D.F.)
Netherlands: Dr. D. L. Leiker (Amsterdam)
People's Republic of China: Dr. Ye Gan Yun (Taizhou)
Philippines: Dr. R. S. Guinto (Cebu)
Portugal: Dr. Salazar Leite (Lisbon)
Spain: Dr. F. Contreras D. (Madrid)
United Kingdom: Dr. S. G. Browne (London)
United Kingdom: Dr. R. J. W. Rees (London)
U.S.A.: Dr. H. L. Arnold, Jr. (Honolulu)
U.S.A.: Dr. P. W. Brand (Carville)
Venezuela: Dr. J. Convit (Caracas)

This JOURNAL is indexed in CURRENT CONTENTS/LIFE SCIENCES, BIOLOGICAL ABSTRACTS, and CHEMICAL ABSTRACTS. Microform available from University Microfilms International, Ann Arbor, Michigan 48106, U.S.A. or London WC1R 4EJ, U.K.

The INTERNATIONAL JOURNAL OF LEPROSY (ISSN 0148-916X) is published quarterly for $40.00 per year for members and $60.00 per year for subscribers by Allen Press, Inc., 1041 New Hampshire St., Lawrence, Kansas 66044, U.S.A. Second-class postage paid at Bloomfield, New Jersey and additional mailing office. POSTMASTER: Send address changes to INTERNATIONAL JOURNAL OF LEPROSY, Business and Circulation Office, 1262 Broad St., Bloomfield, New Jersey 07003, U.S.A.

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 48, Number 1, March 1980

Original Articles — **Page**

Kazda, Jindrich, Irgens, Lorentz M., and Müller, Klaus. Isolation of Non-Cultivable Acid-Fast Bacilli in Sphagnum and Moss Vegetation by Foot Pad Technique in Mice. ---- 1

Pattyn, Stefaan R. and Portaels, Françoise. *In vitro* Cultivation and Characterization of *Mycobacterium lepraemurium*. ---- 7

Wheeler, Paul R. and Draper, Philip. Soluble Blue as a Counterstain in the Ziehl-Neelsen Procedure. A Brief Communication. ---- 15

Seydel, J. K., Richter, M., and Wempe, E. Mechanism of Action of the Folate Blocker Diaminodiphenylsulfone (dapsone, DDS) Studied in *E. coli* Cell-Free Enzyme Extracts in Comparison to Sulfonamides (SA). ---- 18

Bjune, Gunnar. Variation of *in vitro* Lymphocyte Responses to *M. leprae* Antigen in Borderline Tuberculoid Leprosy Patients. ---- 30

Chandi, Sushil M., Chacko, C. J. G., Fritschi, Ernest P., and Job, C. K. Segmental Necrotizing Granulomatous Neuritis of Leprosy. ---- 41

Mukherjee, A., Girdhar, B. K., and Desikan, K. V. Leprous Phlebitis. ---- 48

Lechat, Michel F., Misson, Claudine B., Walter, Joachim, Seal, Kenneth S., and Sansarricq, Hubert. An Information System for Leprosy Control (OMSLEP Recording and Reporting System). ---- 51

Editorials

Vaccination in Leprosy—Observations and Interpretations. (Jacinto Convit, Marian Ulrich, and Nacarid Aranzazu). ---- 62

Mechanism of Action of DDS. (R. C. Hastings). ---- 65

Obituary

Laviron, Paul. ---- 66

Correspondence

At Twenty Years after Shepard's Method of Inoculation of *M. leprae* in the Foot Pads of Mice. (M. Bergel). ---- 67

Reply to Dr. Bergel's Letter to the Editor. (C. C. Shepard). ---- 68

HLA Antigens and Leprosy. (A. Nocera, S. Barocci, and W. Chiarla). ---- 69

Unusual Reaction to Intramuscular Sulfone in Two Leprosy Patients in Malaysia. (A. B. G. Laing). ---- 70

Leprosy and Art in South China. (O. K. Skinsnes). ---- 71

News and Notes ---- 74

Book Reviews ---- 80

Current Literature ---- 82

Special Grantors and Sustaining Members ---- 107

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 48, Number 2, June 1980

Original Articles **Page**

Abe, Masahide, Minagawa, Fumishige, Yoshino, Yuji, Ozawa, Toshiharu, Saikawa, Kazuo, and Saito, Toshi. Fluorescent Leprosy Antibody Absorption (FLA-ABS) Test for Detecting Subclinical Infection with *Mycobacterium leprae*. 109

Rea, Thomas H. and Levan, Norman E. Variations in Dinitrochlorobenzene Responsivity in Untreated Leprosy: Evidence of a Beneficial Role for Anergy. 120

Bechelli, Luiz Marino, Haddad, Nagib, Pagnano, Paul Mucio Guimarães, Neves, Rene Garrido, Melchior, Enzo, Jr., and Fregnan, Roberto Carminatti. Double Blind Trial to Determine the Late Reactivity of Leprosy Patients and Unaffected Persons to Different Concentrations of Armadillo Lepromin in Comparison to Human Lepromin. 126

Ridley, Marian J. and Ridley, Dennis S. Histoid Leprosy. An Ultrastructural Observation. 135

Daver, Shirin M., Dastur, Darab K., Revankar, C. R., and Shah, J. S. Striated Muscle in Four Categories of Leprosy. I. Histology and Histochemistry. 140

Dastur, Darab K. and Daver, Shirin M. Striated Muscle in Four Categories of Leprosy. II. Fine Structural Changes. 149

Rojas-Espinosa, Oscar, Aponte-Vázquez, Jesús, González Cruz, Ofelia, Estrada-Parra, Sergio, and Ortiz, Yolanda. Phagocytosis in Leprosy. III. Defective Adhesive and Endocytic Abilities of Circulating Leukocytes in Lepromatous Leprosy. 159

Mahadevan, P. R. and Antia, Noshir H. Biochemical Alteration in Cells Following Phagocytosis of *M. leprae*—The Consequence—A Basic Concept. 167

Salgame, Padmini R., Birdi, Tannaz J., Mahadevan, P. R., and Antia, Noshir H. Role of Macrophages in Defective Cell Mediated Immunity in Lepromatous Leprosy. I. Factor(s) from Macrophages Affecting Protein Synthesis and Lymphocyte Transformation. 172

Birdi, Tannaz J., Salgame, Padmini R., Mahadevan, P. R., and Antia, Noshir H. Role of Macrophages in Defective Cell Mediated Immunity in Lepromatous Leprosy. II. Macrophage and Lymphocyte Interaction. 178

Mukherjee, Rama, Mahadevan, P. R., and Antia, Noshir H. Organized Nerve Culture. I. A Technique to Study the Effect of *M. leprae* Infection. 183

Mukherjee, Rama, Mahadevan, P. R., and Antia, Noshir H. Organized Nerve Culture. II. DNA Synthesis in Schwann Cells in the Presence of *M. leprae*. 189

Editorial

Immunological Aspects of Leprosy: Ten Years' Activity at the Armauer Hansen Research Institute and Prospects for Further Work. (Morten Harboe). 193

Obituary

Prieto, José Gay. 206

Correspondence

DDS 100 mg Daily Preventing Permanent Nerve Damage in Reversal Reaction. (J. Van der Meulen). 208

Reply to Dr. Van der Meulen's Letter to the Editor. (Ben Naafs). 209

The Fingers in Non-Lepromatous Leprosy. (A. Colin McDougall). ---- 210
Strain 0122, a Contaminating Skin Corynebacterium. (Peter Piot, Eddy Van Dyck, and Stefaan R. Pattyn). ---- 211
Thyroxine and Leprosy. (W. H. Jopling). ---- 211
News and Notes ---- 212
Book Reviews ---- 218
Current Literature ---- 221
Special Grantors and Sustaining Members ---- 245

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 48, Number 3, September 1980

Original Articles **Page**

Stoner, Gerald L., Touw, Jacob, and Belehu, Ayele. An Assay for Antibodies in Leprosy Sera Reacting with Ribonucleoprotein (RNP), a Mycobacterial Ribosomal Antigen, Using Crossed Immunoelectrophoresis with Intermediate Gel. ---- 247

Masuda, Aoi and Scheinberg, Morton A. Peripheral Blood Monocyte Function in Leprosy Patients. ---- 254

Bjorvatn, Bjarne and Kronvall, Göran. Detection of Antigen in *Nocardia caviae* Cross-Reacting with Mycobacterial Antigen No. 21 in *M. leprae* Using a Lepromatous Leprosy Serum Pool as Antibody Reagent. ---- 260

Fieldsteel, A. Howard and Levy, Louis. Combined Rifampin and Dapsone Chemotherapy of *Mycobacterium leprae* Infection of the Neonatally Thymectomized Lewis Rat. ---- 267

Nomaguchi, Hiroko, Nyein, Mar-Mar, Kohsaka, Kenji, Yoneda, Kazuo, and Mori, Tatsuo. The Growth and Drug Sensitivity of *M. lepraemurium* by Tissue Culture Applying Monolayer and Agar Suspension Technique. ---- 277

Rea, Thomas H., Bevans, Lynn, and Taylor, Clive R. The Histopathology of the Spleen from a Patient with Lepromatous Leprosy. ---- 285

Junqueira, Luiz C. U., Montes, Gregorio S., Neto, Estevam Almeida, Barros, Cecy, and Tedesco-Marchese, Antonio J. The Collagen of Permanently Damaged Nerves in Human Leprosy. ---- 291

Mathai, Rachel, Rao, P. S. S. S., and Job, C. K. Risks of Treating Leprosy in a General Hospital. ---- 298

Frist, Thomas F. Employer Acceptance of the Hansen's Disease Patient and Other Handicapped Persons. ---- 303

Editorials

The Transmission of Leprosy in Man. (Christopher L.-H. Huang) ---- 309
Hanseniasis: The Polar Concept as It Stands Today. (F. E. Rabello) ---- 318

Obituaries

Long, Esmond Ray. ---- 322
Rodríguez, José N. ---- 327

Correspondence

The Teaching of Leprosy in Medical Schools: Four and One-Half Hours in Three Years. (A. C. McDougall and A. G. M. Weddell) 329

Unclassified Mycobacterial Strains Susceptible to Dapsone Isolated from the Environment in Central Africa. (F. Portaels) 330

Effect of Purification Procedures on the Viability of *Mycobacterium leprae*. (K. Prabhakaran, E. B. Harris, and W. F. Kirchheimer) 330

Medical Certification of Leprosy Patients and Reservation in Service for the Physically Handicapped, Including Persons with Leprosy. (J. M. Mehta) 332

Leprosy in Archeologically Recovered Bamboo Book in China. (O. K. Skinsnes) .....

News and Notes 334
Book Reviews 339
Current Literature 342
Statement of Financial Condition 365
Special Grantors and Sustaining Members 369

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 48, Number 4, December 1980

Original Articles **Page**

Shepard, Charles C., Minagawa, Fumishige, Van Landingham, Rosalind, and Walker, Laura L. Foot Pad Enlargement as a Measure of Induced Immunity to *Mycobacterium leprae*. 371

Brennan, Patrick J. and Barrow, William W. Evidence for Species-Specific Lipid Antigens in *Mycobacterium leprae*. 382

Navalkar, Ram G., Chaparas, Sotiros D., Lakshiminarayana, C. K., and Kanchana, M. V. Antigenic Evaluation of *Mycobacterium vaccae* in Relation to *Mycobacterium leprae*. 388

Balraj, V., Jesudasan, K., Chacko, C. J. G., Christian, M., Taylor, P. M., Fritschi, E. P., and Job, C. K. Prevalence of Secondary Dapsone Resistance in Gudiyattam Taluk, the Leprosy Control Area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 1. Preliminary Report. 397

Collins, Frank M., Morrison, Norman E., Dhople, Arvind M., and Watson, Susan R. Microscopic Counts Carried Out on *Mycobacterium leprae* and *M. tuberculosis* Suspensions. A Comparison of Three Staining Procedures. 402

Okada, Seitaro, Fukunishi, Yukiko, Mukherjee, A., Ramu, G. and Desikan, K. V. An Improved Embedding Method for Electron Microscopy of Lepromata. 408

Leininger, Joel R., Donham, Kelley J., and Meyers, Wayne M. Leprosy in a Chimpanzee. Postmortem Lesions. 414

Saoji, Arun M., Jariwala, Harshadrai J., and Kelkar, Subhash S. Haptoglobin Phenotypes in Leprosy. 422

Saoji, Arun M., Jariwala, Harshadrai J., and Kelkar, Subhash S. Lactate Dehydrogenase Zymograms of Skin Biopsies in Patients with Leprosy. A Preliminary Report. 426

Kumar, J. H. Ranjit and Verghese, Abraham. Psychiatric Disturbances among Leprosy Patients. An Epidemiological Study. 431

Editorials

Thoughts on the Immunology of Leprosy. (Mauricio Goihman-Yahr). 435

Information Requested from National Leprosy Associations. (R. C. Hastings). 439

Correspondence

Do the Average Bacterial and Morphological Indices Reflect the Patients' True Condition? (Titia Warndorff). 441

Identification Problems of Strain 0122. (C. Cocito and J. Delville). 442

Obituaries

Gilbert, Dr. Maurice. 443

Prast, Dr. Javier Guillen. 443

News and Notes 444

Reviewers 453

Book Reviews 454

Current Literature 458

U.S.–Japan Cooperative Medical Science Program, Fifteenth Joint Leprosy Research Conference, Kagoshima, Japan, 1980 482

International Leprosy Association Organization and Membership, 1980 510

Acknowledgment 524

Index, Volume 48 525

Statement of Ownership, Management, and Circulation 556